

The present and future burden of urinary bladder cancer

World Journal of Urology

27, 289-293

DOI: [10.1007/s00345-009-0383-3](https://doi.org/10.1007/s00345-009-0383-3)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Emerging apoptosis agonists for bladder cancer. <i>Expert Opinion on Emerging Drugs</i> , 2009, 14, 607-618.	1.0	6
2	Spontaneous Rupture of the Upper Urinary Tract Caused by Ureteral Calculi: Effectiveness of Primary Ureteroscopic Treatment. <i>UroToday International Journal</i> , 2009, 02, .	0.1	0
3	Recurrence and Progression of Disease in Non-muscle-Invasive Bladder Cancer: From Epidemiology to Treatment Strategy. <i>European Urology</i> , 2009, 56, 430-442.	0.9	584
4	IS IT TIME TO REDESIGN THE HAEMATURIA CLINIC?. <i>BJU International</i> , 2010, 105, 1478-1479.	1.3	0
5	Cytology and Urinary Markers for the Diagnosis of Bladder Cancer. <i>European Urology Supplements</i> , 2009, 8, 536-541.	0.1	40
6	Female bladder cancer: incidence, treatment, and outcome. <i>Current Opinion in Urology</i> , 2010, 20, 404-408.	0.9	31
7	Lestaurtinib is Cytotoxic to Oxaliplatin-resistant Transitional Cell Carcinoma Cell Line T24 In Vitro. <i>Tzu Chi Medical Journal</i> , 2010, 22, 125-130.	0.4	3
8	Feasibility of T-Cell-Based Adoptive Immunotherapy in the First 12 Patients with Advanced Urothelial Urinary Bladder Cancer. Preliminary Data on a New Immunologic Treatment Based on the Sentinel Node Concept. <i>European Urology</i> , 2010, 58, 105-111.	0.9	27
11	A droplet-based building block approach for bladder smooth muscle cell (SMC) proliferation. <i>Biofabrication</i> , 2010, 2, 014105.	3.7	68
12	Germline genetic markers for urinary bladder cancer risk, prognosis and treatment response. <i>Future Oncology</i> , 2010, 6, 1433-1460.	1.1	15
13	Clinical Epidemiology of Nonurothelial Bladder Cancer: Analysis of The Netherlands Cancer Registry. <i>Journal of Urology</i> , 2010, 183, 915-920.	0.2	99
14	Role of TP53 Arg72Pro polymorphism in urinary bladder cancer predisposition and predictive impact of proline related genotype in advanced tumors in an ethnic Kashmiri population. <i>Cancer Genetics and Cytogenetics</i> , 2010, 203, 263-268.	1.0	20
15	Current Value of Neoadjuvant Chemotherapy Prior to Cystectomy. <i>European Urology Supplements</i> , 2010, 9, 424-427.	0.1	3
16	Taurine - a possible fingerprint biomarker in non-muscle invasive bladder cancer: A pilot study by 1H NMR spectroscopy. <i>Cancer Biomarkers</i> , 2010, 6, 11-20.	0.8	101
17	Cadherin Switching and Bladder Cancer. <i>Journal of Urology</i> , 2010, 184, 423-431.	0.2	91
19	Contemporary management of low-risk bladder cancer. <i>Nature Reviews Urology</i> , 2011, 8, 42-49.	1.9	23
20	Genitourinary Oncology: Current Status and Future Challenges. <i>Frontiers in Oncology</i> , 2011, 1, 32.	1.3	9
21	Bladder Cancer and Cancer Stem Cells: Basic Science and Implications for Therapy. <i>Scientific World Journal</i> , The, 2011, 11, 1187-1194.	0.8	18

#	ARTICLE	IF	CITATIONS
22	Intestinal adenocarcinoma arising in urinary conduits. <i>Oncology Reports</i> , 2012, 27, 371-5.	1.2	5
23	Neoadjuvant Chemotherapy for Muscle Invasive Bladder Cancer. <i>Current Urology</i> , 2011, 5, 57-61.	0.4	1
24	Growth differentiation factor-9 expression is inversely correlated with an aggressive behaviour in human bladder cancer cells. <i>International Journal of Molecular Medicine</i> , 2012, 29, 428-34.	1.8	5
25	Fisetin, a Dietary Flavonoid, Induces Cell Cycle Arrest and Apoptosis through Activation of p53 and Inhibition of NF- κ B Pathways in Bladder Cancer Cells. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2011, 108, 84-93.	1.2	97
26	Construction of a recombinant eukaryotic expression plasmid containing human PDLIM2 gene and its biological activity. <i>Plasmid</i> , 2011, 66, 106-111.	0.4	1
27	Induction of G1 cell cycle arrest and apoptosis by berberine in bladder cancer cells. <i>European Journal of Pharmacology</i> , 2011, 661, 1-7.	1.7	69
28	European Guidelines for the Diagnosis and Management of Upper Urinary Tract Urothelial Cell Carcinomas: 2011 Update. <i>European Urology</i> , 2011, 59, 584-594.	0.9	345
29	Oncologic Outcomes and Survival in pT0 Tumors After Radical Cystectomy in Patients Without Neoadjuvant Chemotherapy: Results from a Large Multicentre Collaborative Study. <i>Annals of Surgical Oncology</i> , 2011, 18, 3833-3838.	0.7	11
30	Detection of smoothelin expression in the urinary bladder is strongly dependent on pretreatment conditions: a critical analysis with possible consequences for cancer staging. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2011, 458, 665-670.	1.4	13
31	Association of Bladder Cancer Risk with an NAD(P)H:Quinone Oxidoreductase Polymorphism in an Ethnic Kashmiri Population. <i>Biochemical Genetics</i> , 2011, 49, 417-426.	0.8	9
32	External validation and applicability of the EORTC risk tables for non-muscle-invasive bladder cancer. <i>World Journal of Urology</i> , 2011, 29, 409-414.	1.2	52
33	Current evidence for transurethral laser therapy of non-muscle invasive bladder cancer. <i>World Journal of Urology</i> , 2011, 29, 433-442.	1.2	65
34	Histone deacetylases (HDACs) in XPC gene silencing and bladder cancer. <i>Journal of Hematology and Oncology</i> , 2011, 4, 17.	6.9	43
35	Role of chemotherapy in upper urinary tract urothelial cell cancers. <i>Future Oncology</i> , 2011, 7, 1067-1075.	1.1	0
36	Clinical Significance of <i>CDH13</i> Promoter Methylation in Serum Samples from Patients with Bladder Transitional Cell Carcinoma. <i>Journal of International Medical Research</i> , 2011, 39, 179-186.	0.4	26
37	Clinical Significance of T-Cadherin Tissue Expression in Patients with Bladder Transitional Cell Carcinoma. <i>Urologia Internationalis</i> , 2011, 86, 340-345.	0.6	12
38	Massive Upper Gastrointestinal Bleeding Secondary to Duodenal Metastasis of Transitional Cell Carcinoma of the Urinary Bladder. <i>Case Reports in Gastroenterology</i> , 2011, 5, 246-248.	0.3	3
39	European genome-wide association study identifies SLC14A1 as a new urinary bladder cancer susceptibility gene. <i>Human Molecular Genetics</i> , 2011, 20, 4268-4281.	1.4	134

#	ARTICLE	IF	CITATIONS
40	Urothelial tumor initiation requires deregulation of multiple signaling pathways: implications in target-based therapies. <i>Carcinogenesis</i> , 2012, 33, 770-780.	1.3	20
41	The effect of gender on oncological outcomes in patients who have undergone radical cystectomy due to bladder cancer. <i>Turk Uroloji Dergisi</i> , 2012, 38, 126-131.	0.4	0
42	Intravesical Recurrence after Surgical Management of Urothelial Carcinoma of the Upper Urinary Tract. <i>Urologia Internationalis</i> , 2012, 89, 71-77.	0.6	25
43	Surveillance and Treatment of Non-Muscle-Invasive Bladder Cancer in the USA. <i>Advances in Urology</i> , 2012, 2012, 1-8.	0.6	31
44	Lack of Association between hOGG1 Ser326Cys Polymorphism and the Risk of Bladder Cancer: A Meta-Analysis. <i>Urologia Internationalis</i> , 2012, 88, 88-94.	0.6	8
45	Over-expression of HER-2 is associated with the stage in carcinomas of the urinary bladder. <i>Libyan Journal of Medicine</i> , 2012, 7, 14694.	0.8	11
46	Epigenetic Alterations in Bladder Cancer and Their Potential Clinical Implications. <i>Advances in Urology</i> , 2012, 2012, 1-11.	0.6	24
47	Simultaneous siRNA-mediated knockdown of antiapoptotic BCL2, Bcl-xL, XIAP and survivin in bladder cancer cells. <i>International Journal of Oncology</i> , 2012, 41, 1271-7.	1.4	17
48	Bladder cancer: risk factors, diagnosis and treatment. <i>Cancer Nursing Practice</i> , 2012, 11, 30-37.	0.2	5
49	The Association of RAS Association Domain Family Protein1A (RASSF1A) Methylation States and Bladder Cancer Risk: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2012, 7, e48300.	1.1	20
50	Follow-up procedures for non-muscle-invasive bladder cancer: an update. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 1229-1241.	1.1	17
51	Polymeric Nanoparticles with Encapsulated Superparamagnetic Iron Oxide and Conjugated Cisplatin for Potential Bladder Cancer Therapy. <i>Biomacromolecules</i> , 2012, 13, 2513-2520.	2.6	79
52	Is it oncologically safe performing simultaneous transurethral resection of the bladder and prostate? A meta-analysis on 1,234 patients. <i>International Urology and Nephrology</i> , 2012, 44, 1325-1333.	0.6	13
53	Alloplastic bladder substitution: are we making progress?. <i>International Urology and Nephrology</i> , 2012, 44, 1295-1303.	0.6	14
54	Optimising Existing Therapeutic Strategies for the Treatment of Non-Muscle-Invasive Bladder Cancer: The Role of Intensive Neoadjuvant Intravesical Mitomycin C. <i>European Urology</i> , 2012, 62, 803-805.	0.9	6
55	Gender and Body Mass Index as Risk Factors for Bladder Perforation During Primary Transurethral Resection of Bladder Tumors. <i>Journal of Urology</i> , 2012, 187, 1566-1570.	0.2	36
56	Urinary BLCA-4 level is useful to detect upper urinary tract urothelial cell carcinoma. <i>Actas Urológicas Españolas (English Edition)</i> , 2012, 36, 597-602.	0.2	1
58	Best practice in the treatment of nonmuscle invasive bladder cancer. <i>Therapeutic Advances in Urology</i> , 2012, 4, 13-32.	0.9	125

#	ARTICLE	IF	CITATIONS
59	Discrepancy between clinical staging through bimanual palpation and pathological staging after cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2012, 30, 247-251.	0.8	39
60	Recent advances in urinary bladder cancer detection. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 929-939.	1.1	14
61	MicroRNA-449a acts as a tumor suppressor in human bladder cancer through the regulation of pocket proteins. <i>Cancer Letters</i> , 2012, 320, 40-47.	3.2	79
62	Selenoproteins in bladder cancer. <i>Clinica Chimica Acta</i> , 2012, 413, 847-854.	0.5	24
64	European guidelines for the diagnosis and management of upper urinary tract urothelial cell carcinomas: 2011 update. <i>Actas Urológicas Españolas (English Edition)</i> , 2012, 36, 2-14.	0.2	21
65	Overexpression of TG-Interacting Factor Is Associated with Worse Prognosis in Upper Urinary Tract Urothelial Carcinoma. <i>American Journal of Pathology</i> , 2012, 181, 1044-1055.	1.9	30
66	Current strategies in the treatment of non-muscle-invasive bladder cancer. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 1097-1106.	1.1	2
67	Side Population in Human Non-Muscle Invasive Bladder Cancer Enriches for Cancer Stem Cells That Are Maintained by MAPK Signalling. <i>PLoS ONE</i> , 2012, 7, e50690.	1.1	42
68	N-Acetyltransferase 1 (<i>NAT1</i>) Genotype: A Risk Factor for Urinary Bladder Cancer in a Lebanese Population. <i>Journal of Oncology</i> , 2012, 2012, 1-10.	0.6	13
69	Reduced expression of MTUS1 mRNA is correlated with poor prognosis in bladder cancer. <i>Oncology Letters</i> , 2012, 4, 113-118.	0.8	20
70	Urine and Serum Cathepsin B Concentrations in the Transitional Cell Carcinoma of the Bladder. <i>Journal of Clinical Laboratory Analysis</i> , 2012, 26, 61-65.	0.9	8
71	Detection of mitochondrial deoxyribonucleic acid alterations in urine from urothelial cell carcinoma patients. <i>International Journal of Cancer</i> , 2012, 131, 158-164.	2.3	23
73	Restaging Transurethral Resection of Bladder Tumor for High-risk Stage Ta and T1 Bladder Cancer. <i>Current Urology Reports</i> , 2012, 13, 109-114.	1.0	30
75	Cyclin-dependent kinase 4 is a novel target in microRNA-mediated cell cycle arrest in bladder cancer cells. <i>FEBS Letters</i> , 2012, 586, 442-447.	1.3	85
76	<i>KRAS</i> mutation is present in a small subset of primary urinary bladder adenocarcinomas. <i>Histopathology</i> , 2012, 61, 1036-1042.	1.6	23
77	The value of extended transurethral resection of bladder tumour (TURBT) in the treatment of bladder cancer. <i>BJU International</i> , 2012, 110, E76-9.	1.3	55
78	Primary clear cell adenocarcinoma of the bladder with recurrence: a case report and literature review. <i>World Journal of Surgical Oncology</i> , 2012, 10, 33.	0.8	14
79	Comprehensive pathway-based interrogation of genetic variations in the nucleotide excision DNA repair pathway and risk of bladder cancer. <i>Cancer</i> , 2012, 118, 205-215.	2.0	13

#	ARTICLE	IF	CITATIONS
80	Promoter methylation of H-cadherin is a potential biomarker in patients with bladder transitional cell carcinoma. <i>International Urology and Nephrology</i> , 2012, 44, 111-117.	0.6	15
81	Target protein for Xklp2 (TPX2), a microtubule-related protein, contributes to malignant phenotype in bladder carcinoma. <i>Tumor Biology</i> , 2013, 34, 4089-4100.	0.8	38
82	IMAC Fractionation in Combination with LC-MS Reveals H2B and NIF-1 Peptides As Potential Bladder Cancer Biomarkers. <i>Journal of Proteome Research</i> , 2013, 12, 3969-3979.	1.8	20
83	Clinical applications of capillary electrophoresis coupled to mass spectrometry in biomarker discovery: Focus on bladder cancer. <i>Proteomics - Clinical Applications</i> , 2013, 7, 779-793.	0.8	26
84	MicroRNA-409-3p Inhibits Migration and Invasion of Bladder Cancer Cells via Targeting c-Met. <i>Molecules and Cells</i> , 2013, 36, 62-68.	1.0	77
85	Feasibility of radical cystectomy in exclusive spinal and/or epidural anaesthesia. <i>World Journal of Urology</i> , 2013, 31, 1279-1284.	1.2	7
86	Do pure squamous cell carcinomas and urothelial carcinomas have similar prognosis after radical cystectomy?. <i>World Journal of Urology</i> , 2013, 31, 1177-1182.	1.2	8
87	Unaltered oncological outcomes of radical cystectomy with extended lymphadenectomy over three decades. <i>BJU International</i> , 2013, 112, E51-8.	1.3	82
88	Slug contributes to cadherin switch and malignant progression in muscle-invasive bladder cancer development. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 1751-1760.	0.8	39
89	Office-based Management of Nonmuscle Invasive Bladder Cancer. <i>Urologic Clinics of North America</i> , 2013, 40, 473-479.	0.8	8
90	Computed tomography-virtual cystoscopy in the evaluation of a bladder mass: Could it replace standard conventional cystoscopy?. <i>Arab Journal of Urology Arab Association of Urology</i> , 2013, 11, 369-374.	0.7	4
91	Estimation of bladder cancer projections in Spain. <i>Actas Urológicas Españolas (English Edition)</i> , 2013, 37, 286-291.	0.2	3
93	MicroRNA-101 suppresses motility of bladder cancer cells by targeting c-Met. <i>Biochemical and Biophysical Research Communications</i> , 2013, 435, 82-87.	1.0	58
94	The role of urine markers, white light cystoscopy and fluorescence cystoscopy in recurrence, progression and follow-up of non-muscle invasive bladder cancer. <i>World Journal of Urology</i> , 2014, 32, 651-9.	1.2	23
95	FTIR spectroscopy of biofluids revisited: an automated approach to spectral biomarker identification. <i>Analyst</i> , 2013, 138, 4092.	1.7	93
96	HRAS T81C polymorphism modulates risk of urinary bladder cancer and predicts advanced tumors in ethnic Kashmiri population. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 487-492.	0.8	17
97	MicroRNA-490-5p inhibits proliferation of bladder cancer by targeting c-Fos. <i>Biochemical and Biophysical Research Communications</i> , 2013, 441, 976-981.	1.0	62
99	BCG shortage in Europe. <i>Preventive Medicine</i> , 2013, 57, 146.	1.6	11

#	ARTICLE	IF	CITATIONS
100	Bladder cancer discussed in the internet: a systematic analysis of gender differences of initial posters on an online discussion board. SpringerPlus, 2013, 2, 445.	1.2	2
101	The long road to bladder sparing in muscle invasive cancer. Lancet Oncology, The, 2013, 14, 795-796.	5.1	0
102	Epidemiology and Risk Factors of Urothelial Bladder Cancer. European Urology, 2013, 63, 234-241.	0.9	1,572
103	Urothelial carcinomas of the upper urinary tract are now recognised as a true and distinct entity from bladder cancer and belong fully to the broad spectrum of onco-urologic neoplasms. World Journal of Urology, 2013, 31, 1-3.	1.2	6
104	Epithelial-mesenchymal transition, a novel target of sulforaphane via COX-2/MMP2, 9/Snail, ZEB1 and miR-200c/ZEB1 pathways in human bladder cancer cells. Journal of Nutritional Biochemistry, 2013, 24, 1062-1069.	1.9	110
105	The roles of LSD1-mediated epigenetic modifications in maintaining the pluripotency of bladder cancer stem cells. Medical Hypotheses, 2013, 81, 823-825.	0.8	14
106	The effect of preoperative clinical variables on the 30- and 90-day morbidity and mortality after radical cystectomy: A single-centre study. Arab Journal of Urology Arab Association of Urology, 2013, 11, 152-158.	0.7	5
107	Estimación de las proyecciones del cáncer de vejiga en España. Actas Urológicas Españolas, 2013, 37, 286-291.	0.3	8
108	Searching for urine biomarkers of bladder cancer recurrence using a liquid chromatography-mass spectrometry and capillary electrophoresis-mass spectrometry metabolomics approach. Journal of Chromatography A, 2013, 1318, 163-170.	1.8	117
109	Results of a Phase 1 Dose Escalation Study of Intravesical TMX-101 in Patients with Nonmuscle Invasive Bladder Cancer. Journal of Urology, 2013, 189, 2077-2082.	0.2	35
110	uCyt+/ImmunoCyt and cytology in the detection of urothelial carcinoma. Cancer Cytopathology, 2013, 121, 392-397.	1.4	50
111	Overexpression of tumour-associated carbohydrate antigen sialyl-Tn in advanced bladder tumours. Molecular Oncology, 2013, 7, 719-731.	2.1	79
112	Diabetes Mellitus and Risk of Bladder Cancer: A Meta-Analysis of Cohort Studies. PLoS ONE, 2013, 8, e58079.	1.1	48
113	The Clinical Significance of PCDH10 Promoter Methylation in Patients with Bladder Transitional Cell Carcinoma. Urologia Internationalis, 2013, 90, 219-224.	0.6	11
114	European Guidelines on Upper Tract Urothelial Carcinomas: 2013 Update. European Urology, 2013, 63, 1059-1071.	0.9	414
115	Recent advances in the diagnosis and treatment of bladder cancer. BMC Medicine, 2013, 11, 13.	2.3	142
116	Oncogenic role of fibroblast growth factor receptor 3 in tumorigenesis of urinary bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 398-406.	0.8	42
117	Safety and efficacy of 120w high performance system greenlight laser vaporization for non-muscle-invasive bladder cancer. Journal of X-Ray Science and Technology, 2013, 21, 309-316.	0.7	16

#	ARTICLE	IF	CITATIONS
118	Endometrial stem cell differentiation into smooth muscle cell: a novel approach for bladder tissue engineering in women. <i>BJU International</i> , 2013, 112, 854-863.	1.3	49
119	Downregulation of CDH13 Expression Promotes Invasiveness of Bladder Transitional Cell Carcinoma. <i>Urologia Internationalis</i> , 2013, 90, 225-232.	0.6	16
120	Radical Cystectomy and Lymphadenectomy to Two Patients with Pelvic Kidney: Surgical Pitfalls and Considerations. <i>Case Reports in Medicine</i> , 2013, 2013, 1-3.	0.3	5
121	Urinary Bladder Cancer Susceptibility Markers. What Do We Know about Functional Mechanisms?. <i>International Journal of Molecular Sciences</i> , 2013, 14, 12346-12366.	1.8	30
122	Prophylactic Intravesical Chemotherapy to Prevent Bladder Tumors after Nephroureterectomy for Primary Upper Urinary Tract Urothelial Carcinomas: A Systematic Review and Meta-Analysis. <i>Urologia Internationalis</i> , 2013, 91, 291-296.	0.6	69
123	The TREK2 Channel Is Involved in the Proliferation of 253J Cell, a Human Bladder Carcinoma Cell. <i>Korean Journal of Physiology and Pharmacology</i> , 2013, 17, 511.	0.6	13
124	Update on bladder cancer diagnosis and management. <i>Trends in Urology & Men's Health</i> , 2013, 4, 7-11.	0.2	2
125	Smoking is associated with lower age, higher grade, higher stage, and larger size of malignant bladder tumors at diagnosis. <i>International Journal of Cancer</i> , 2013, 133, 446-454.	2.3	35
126	An essential role for decorin in bladder cancer invasiveness. <i>EMBO Molecular Medicine</i> , 2013, 5, 1835-1851.	3.3	45
127	Expert review: an update in current and developing intravesical therapies for non-muscle-invasive bladder cancer. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 1257-1268.	1.1	4
128	Hypoxia regulates FGFR3 expression via HIF-1 α and miR-100 and contributes to cell survival in non-muscle invasive bladder cancer. <i>British Journal of Cancer</i> , 2013, 109, 50-59.	2.9	55
129	Urinary tuberculosis is associated with the development of urothelial carcinoma but not renal cell carcinoma: a nationwide cohort study in Taiwan. <i>British Journal of Cancer</i> , 2013, 109, 2933-2940.	2.9	13
130	Downregulation of protocadherin-10 expression correlates with malignant behaviour and poor prognosis in human bladder cancer. <i>Journal of International Medical Research</i> , 2013, 41, 38-47.	0.4	10
131	A comparison of patient and tumour characteristics in two <sc>UK</sc> bladder cancer cohorts separated by 20 years. <i>BJU International</i> , 2013, 112, 169-175.	1.3	35
132	Dual role of TGFBR3 in bladder cancer. <i>Oncology Reports</i> , 2013, 30, 1301-1308.	1.2	18
133	Heterogeneity of uroplakin localization in human normal urothelium, papilloma and papillary carcinoma. <i>Radiology and Oncology</i> , 2013, 47, 338-345.	0.6	19
134	Snail expression and outcome in T1 high-grade and T2 bladder cancer: a retrospective immunohistochemical analysis. <i>BMC Urology</i> , 2013, 13, 73.	0.6	12
135	Candidate of metastasis 1 regulates in vitro growth and invasion of bladder cancer cells. <i>International Journal of Oncology</i> , 2013, 42, 1249-1256.	1.4	4

#	ARTICLE	IF	CITATIONS
136	Expression of extracellular matrix metalloproteinase inducer and fascin in urinary bladder cancer: Correlation with clinicopathological characteristics. <i>Molecular and Clinical Oncology</i> , 2013, 1, 297-304.	0.4	15
137	Concurrent granulomatous hepatitis, pneumonitis and sepsis as a complication of intravesical BCG immunotherapy. <i>BMJ Case Reports</i> , 2013, 2013, bcr2013200624-bcr2013200624.	0.2	14
138	New therapeutic targets in the management of urothelial carcinoma of the bladder. <i>Research and Reports in Urology</i> , 2013, 5, 53.	0.6	5
139	Expression of Beclin 1 in Bladder Cancer and Its Clinical Significance. <i>International Journal of Biological Markers</i> , 2013, 28, 56-62.	0.7	14
140	Comparison of Radical Cystectomy with Conservative Treatment in Geriatric (80) Patients with Muscle-Invasive Bladder Cancer. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2013, 39, 622-630.	0.7	15
141	Dracorhodin perchlorate induces apoptosis in bladder cancer cells through Bcl-2, Bcl-XL, survivin down-regulation and caspase-3 activation. <i>Bangladesh Journal of Pharmacology</i> , 2013, 8, .	0.1	1
142	CSTP1, a Novel Protein Phosphatase, Blocks Cell Cycle, Promotes Cell Apoptosis, and Suppresses Tumor Growth of Bladder Cancer by Directly Dephosphorylating Akt at Ser473 Site. <i>PLoS ONE</i> , 2013, 8, e65679.	1.1	27
143	Inhibitory Role of the Small Leucine-Rich Proteoglycan Biglycan in Bladder Cancer. <i>PLoS ONE</i> , 2013, 8, e80084.	1.1	49
144	Induction of Apoptosis by Costunolide in Bladder Cancer Cells is Mediated through ROS Generation and Mitochondrial Dysfunction. <i>Molecules</i> , 2013, 18, 1418-1433.	1.7	96
145	Characteristic patterns of microRNA expression in human bladder cancer. <i>Frontiers in Genetics</i> , 2012, 3, 310.	1.1	32
146	Can Neutrophil-Lymphocyte Ratio and Lymph Node Density Be Used as Prognostic Factors in Patients Undergoing Radical Cystectomy?. <i>Scientific World Journal, The</i> , 2013, 2013, 1-5.	0.8	30
147	NBN Gene Polymorphisms and Cancer Susceptibility: A Systemic Review. <i>Current Genomics</i> , 2013, 14, 425-440.	0.7	19
148	Jaceosidin inhibits proliferation of human bladder cancer T24 cells through induction of cell cycle arrest and apoptosis. <i>Bangladesh Journal of Pharmacology</i> , 2013, 8, .	0.1	3
149	Peri-Operative Morbidity Associated with Radical Cystectomy in a Multicenter Database of Community and Academic Hospitals. <i>PLoS ONE</i> , 2014, 9, e111281.	1.1	84
150	PM00104 (Zalypsis®): A Marine Derived Alkylating Agent. <i>Molecules</i> , 2014, 19, 12328-12335.	1.7	28
151	The effects and effectiveness of electromotive drug administration and chemohyperthermia for treating non-muscle invasive bladder cancer. <i>Annals of the Royal College of Surgeons of England</i> , 2014, 96, 415-419.	0.3	21
152	Factors affecting recurrence and progression in intravesical BCG treated high grade non muscle invasive bladder cancer. <i>Pakistan Journal of Medical Sciences</i> , 2014, 30, 326-30.	0.3	10
153	Current Evidence for the Treatment of Bladder Cancer. <i>The Ewha Medical Journal</i> , 2014, 37, 1.	0.1	1

#	ARTICLE	IF	CITATIONS
155	Tubeimoside-1 upregulates p21 expression and induces apoptosis and G2/M phase cell cycle arrest in human bladder cancer T24 cells. Bangladesh Journal of Pharmacology, 2014, 9, .	0.1	5
157	<i>LINE1</i> methylation levels associated with increased bladder cancer risk in pre-diagnostic blood DNA among US (PLCO) and European (ATBC) cohort study participants. Epigenetics, 2014, 9, 404-415.	1.3	35
158	Current and recent clinical trials for perioperative systemic therapy for muscle invasive bladder cancer: a systematic review. BMC Cancer, 2014, 14, 966.	1.1	24
159	Medical follow-up for workers exposed to bladder carcinogens: the French evidence-based and pragmatic statement. BMC Public Health, 2014, 14, 1155.	1.2	6
160	M2muscarinic receptors inhibit cell proliferation and migration in urothelial bladder cancer cells. Cancer Biology and Therapy, 2014, 15, 1489-1498.	1.5	29
161	Metastasis to Sartorius Muscle from a Muscle Invasive Bladder Cancer. Case Reports in Medicine, 2014, 2014, 1-3.	0.3	7
162	Prognostic value of serum nicotinamide phosphoribosyltransferase in patients with bladder cancer. Croatian Medical Journal, 2014, 55, 507-513.	0.2	18
163	S292: Risk factors associated with postoperative complications following radical cystectomy. European Urology Supplements, 2014, 13, e1600.	0.1	0
164	Diagnosis of bladder cancer from the voided urine specimens using multi-target fluorescence in situ hybridization. Oncology Letters, 2014, 7, 325-330.	0.8	2
165	Licochalcone A inhibiting proliferation of bladder cancer T24 cells by inducing reactive oxygen species production. Bio-Medical Materials and Engineering, 2014, 24, 1019-1025.	0.4	19
166	Lack of association between MTHFR Ala222Val and Glu429Ala polymorphisms and bladder cancer risk: A meta-analysis of case-control studies. Biomedical Reports, 2014, 2, 396-403.	0.9	5
167	Analysis of Results of Recurrence and Progression Rates of High-Grade Ta Bladder Cancer and Comparison with Results of High-Grade T1. Urologia, 2014, 81, 237-241.	0.3	2
168	Differentially expressed genes and interacting pathways in bladder cancer revealed by bioinformatic analysis. Molecular Medicine Reports, 2014, 10, 1746-1752.	1.1	8
170	Clinical significance of the reduction of UT-B expression in urothelial carcinoma of the bladder. Pathology Research and Practice, 2014, 210, 799-803.	1.0	9
173	N-l-ε-guanyl-L-α-diaminoheptane sensitizes bladder cancer cells to doxorubicin by preventing epithelial-mesenchymal transition through inhibition of eukaryotic translation initiation factor 5 A 2 activation. Cancer Science, 2014, 105, 219-227.	1.7	31
175	S117: Patterns, risks and outcomes of urethral recurrence after radical cystectomy for urothelial cancer; over 20 year single center experience. European Urology Supplements, 2014, 13, e1482.	0.1	0
176	It's in your blood: spectral biomarker candidates for urinary bladder cancer from automated FTIR spectroscopy. Journal of Biophotonics, 2014, 7, 210-221.	1.1	69
178	Protocadherin 17 promoter methylation in tumour tissue from patients with bladder transitional cell carcinoma. Journal of International Medical Research, 2014, 42, 292-299.	0.4	23

#	ARTICLE	IF	CITATIONS
179	Urinary Bladder Cancer in Dogs, a Naturally Occurring Model for Cancer Biology and Drug Development. <i>ILAR Journal</i> , 2014, 55, 100-118.	1.8	202
180	Metformin sensitizes human bladder cancer cells to TRAIL-induced apoptosis through mTOR/S6K1-mediated downregulation of c-FLIP. <i>Anti-Cancer Drugs</i> , 2014, 25, 887-897.	0.7	31
181	A High Frequency of Activating Extracellular Domain <i>ERBB2</i> (<i>HER2</i>) Mutation in Micropapillary Urothelial Carcinoma. <i>Clinical Cancer Research</i> , 2014, 20, 68-75.	3.2	120
182	Protocadherin-17 promoter methylation in serum-derived DNA is associated with poor prognosis of bladder cancer. <i>Journal of International Medical Research</i> , 2014, 42, 35-41.	0.4	25
183	Urea Transporters. <i>Sub-Cellular Biochemistry</i> , 2014, , .	1.0	11
184	Treatment Outcome and Relevance of Palliative Chemotherapy in Urachal Cancer. <i>Chemotherapy</i> , 2014, 60, 73-80.	0.8	22
185	Silencing B7-H1 enhances the anti-tumor effect of bladder cancer antigen-loaded dendritic cell vaccine in vitro. <i>OncoTargets and Therapy</i> , 2014, 7, 1389.	1.0	14
186	Cisplatin-induced epigenetic activation of miR-34a sensitizes bladder cancer cells to chemotherapy. <i>Molecular Cancer</i> , 2014, 13, 8.	7.9	49
187	Her2/neu expression in urothelial dysplasia, carcinoma in situ, and superficial urothelial carcinoma and its value in assessing the response to BCG therapy. <i>Egyptian Journal of Pathology</i> , 2014, 34, 25-31.	0.0	1
188	Agricultural Workers and Urinary Bladder Cancer Risk in Egypt. <i>Archives of Environmental and Occupational Health</i> , 2014, 69, 3-10.	0.7	17
189	Anesthesia for Urologic Surgery. , 2014, , .		0
190	Selective binding of lectins to normal and neoplastic urothelium in rat and mouse bladder carcinogenesis models. <i>Protoplasma</i> , 2014, 251, 49-59.	1.0	27
191	Time trends of cancer incidence and mortality in Catalonia during 1993â€“2007. <i>Clinical and Translational Oncology</i> , 2014, 16, 18-28.	1.2	37
192	Genetic variants in NAMPT predict bladder cancer risk and prognosis in individuals from southwest Chinese Han group. <i>Tumor Biology</i> , 2014, 35, 4031-4040.	0.8	22
193	Decision Tools for Radiation Oncology. <i>Medical Radiology</i> , 2014, , .	0.0	2
194	A comprehensive evaluation of bladder cancer epidemiology and outcomes in Australia. <i>International Urology and Nephrology</i> , 2014, 46, 1351-1360.	0.6	16
195	Urinary calprotectin: a new diagnostic marker in urothelial carcinoma of the bladder. <i>World Journal of Urology</i> , 2014, 32, 1485-1492.	1.2	31
196	EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2013 Guidelines. <i>European Urology</i> , 2014, 65, 778-792.	0.9	868

#	ARTICLE	IF	CITATIONS
197	Prognostic value of inflammation or granuloma after intravesical BCG in non-muscle-invasive bladder cancer. <i>BJU International</i> , 2014, 113, E22-7.	1.3	27
198	Boldine induces cell cycle arrest and apoptosis in T24 human bladder cancer cell line via regulation of ERK, AKT, and GSK-3 β . <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 36.e1-36.e9.	0.8	41
199	Comprehensive analyses of DNA repair pathways, smoking and bladder cancer risk in Los Angeles and Shanghai. <i>International Journal of Cancer</i> , 2014, 135, 335-347.	2.3	22
200	EGFR alterations and EML4-ALK rearrangement in primary adenocarcinoma of the urinary bladder. <i>Modern Pathology</i> , 2014, 27, 107-112.	2.9	12
201	Imaging in Clinical Oncology. , 2014, , .		2
202	Urinary EpCAM in urothelial bladder cancer patients: characterisation and evaluation of biomarker potential. <i>British Journal of Cancer</i> , 2014, 110, 679-685.	2.9	35
203	Risk factors for intravesical recurrence after radical nephroureterectomy for upper tract urothelial carcinoma: A meta-analysis ¹ These authors equally dedicated to this article.. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 989-1002.	0.8	32
204	The Safe and Economical Care of Ta Bladder Cancer. <i>Urology Practice</i> , 2014, 1, 176-183.	0.2	1
205	Current evidence for transurethral en bloc resection of non-muscle-invasive bladder cancer. <i>Minimally Invasive Therapy and Allied Technologies</i> , 2014, 23, 206-213.	0.6	97
206	The Health Economics of Bladder Cancer: An Updated Review of the Published Literature. <i>Pharmacoeconomics</i> , 2014, 32, 1093-1104.	1.7	166
207	p21WAF1 mediates the IL-15-induced migration and invasion of human bladder cancer 5637 cells via the ERK1/2/NF- κ B/MMP-9 pathway. <i>International Immunopharmacology</i> , 2014, 22, 59-65.	1.7	14
208	Functionalized Mesoporous Silica Nanoparticles with Mucoadhesive and Sustained Drug Release Properties for Potential Bladder Cancer Therapy. <i>Langmuir</i> , 2014, 30, 6151-6161.	1.6	101
209	Multimodal management of muscle-invasive bladder cancer. <i>Current Problems in Cancer</i> , 2014, 38, 80-108.	1.0	76
210	eIF3a is over-expressed in urinary bladder cancer and influences its phenotype independent of translation initiation. <i>Cellular Oncology (Dordrecht)</i> , 2014, 37, 253-267.	2.1	48
211	Clinical significance of protocadherin 8 (PCDH8) promoter methylation in non-muscle invasive bladder cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2014, 33, 68.	3.5	26
212	Genome-wide association study yields variants at 20p12.2 that associate with urinary bladder cancer. <i>Human Molecular Genetics</i> , 2014, 23, 5545-5557.	1.4	46
213	Nrf2- and ATF4-Dependent Upregulation of xCT Modulates the Sensitivity of T24 Bladder Carcinoma Cells to Proteasome Inhibition. <i>Molecular and Cellular Biology</i> , 2014, 34, 3421-3434.	1.1	163
214	The impact of tumor size on outcomes in patients with upper urinary tract urothelial carcinoma. <i>International Urology and Nephrology</i> , 2014, 46, 563-569.	0.6	25

#	ARTICLE	IF	CITATIONS
215	The impact of cyclin D1 overexpression on the prognosis of bladder cancer: a meta-analysis. <i>World Journal of Surgical Oncology</i> , 2014, 12, 55.	0.8	25
216	Relationships Between <i>CYP1A1</i> Genetic Polymorphisms and Bladder Cancer Risk: A Meta-Analysis. <i>DNA and Cell Biology</i> , 2014, 33, 171-181.	0.9	6
217	The Global Risk of Bladder Cancer: Let's Just Do Something About It!. <i>European Urology</i> , 2014, 66, 74-75.	0.9	4
218	Accurate detection of upper tract urothelial carcinoma in tissue and urine by means of quantitative GDF15, TMEFF2 and VIM promoter methylation. <i>European Journal of Cancer</i> , 2014, 50, 226-233.	1.3	47
219	Combined Chemohyperthermia: 10-Year Single Center Experience in 160 Patients with Nonmuscle Invasive Bladder Cancer. <i>Journal of Urology</i> , 2014, 192, 708-713.	0.2	56
220	Bladder cancer in HIV-infected adults: an emerging concern?. <i>Journal of the International AIDS Society</i> , 2014, 17, 19647.	1.2	2
221	Screening for Prostate Cancer: New Markers and Future Aspects. , 2014, , 541-568.		0
222	Knockdown of Bmi1 inhibits the stemness properties and tumorigenicity of human bladder cancer stem cell-like side population cells. <i>Oncology Reports</i> , 2014, 31, 727-736.	1.2	29
223	Overexpression of flotillin-1 is involved in proliferation and recurrence of bladder transitional cell carcinoma. <i>Oncology Reports</i> , 2014, 32, 748-754.	1.2	16
224	Tibial Metastasis from Muscle Invasive Bladder Carcinoma: An Unusual Site. <i>Current Urology</i> , 2014, 7, 160-162.	0.4	0
225	Aplicaci3n de nomogramas en M3xico para c3ncer de vejiga en pacientes del Hospital General 3eDr. Manuel Gea Gonz3lez. <i>Revista Mexicana De Urologia</i> , 2014, 74, 3-8.	0.0	2
226	The combinatory effects of PPAR-Î³ agonist and survivin inhibition on the cancer stem-like phenotype and cell proliferation in bladder cancer cells. <i>International Journal of Molecular Medicine</i> , 2014, 34, 262-268.	1.8	22
227	In vitro and in vivo targeting of bladder carcinoma with metformin in combination with cisplatin. <i>Oncology Letters</i> , 2015, 10, 975-981.	0.8	19
228	Diagnosis and treatment of non-muscle-invasive bladder cancer. <i>Trends in Urology & Men's Health</i> , 2015, 6, 23-27.	0.2	3
229	The role of cystectomy in elderly patients 3e a multicentre analysis. <i>BJU International</i> , 2015, 116, 73-79.	1.3	41
230	Perioperative chemotherapy for muscle invasive bladder cancer. <i>Current Opinion in Supportive and Palliative Care</i> , 2015, 9, 249-254.	0.5	1
231	Robotic versus open radical cystectomy for bladder cancer in adults. <i>The Cochrane Library</i> , 0, , .	1.5	3
232	Bioinformatics analysis of the target gene of fibroblast growth factor receptor 3 in bladder cancer and associated molecular mechanisms. <i>Oncology Letters</i> , 2015, 10, 543-549.	0.8	7

#	ARTICLE	IF	CITATIONS
233	Î³-secretase inhibitor inhibits bladder cancer cell drug resistance and invasion by reducing epithelial-mesenchymal transition. <i>Molecular Medicine Reports</i> , 2015, 12, 2821-2827.	1.1	7
234	Predictive Value of Clinicopathological Markers for the Metachronous Bladder Cancer and Prognosis of Upper Tract Urothelial Carcinoma. <i>Scientific Reports</i> , 2014, 4, 4015.	1.6	18
235	Decreased expression of protein tyrosine phosphatase non-receptor type 12 is involved in the proliferation and recurrence of bladder transitional cell carcinoma. <i>Oncology Letters</i> , 2015, 10, 1620-1626.	0.8	6
236	MiR-186 suppresses the growth and metastasis of bladder cancer by targeting NSBP1. <i>Diagnostic Pathology</i> , 2015, 10, 146.	0.9	49
237	Aberrant methylation of CDH11 predicts a poor outcome for patients with bladder cancer. <i>Oncology Letters</i> , 2015, 10, 647-652.	0.8	23
238	Global surgery â€“ how much of the burden isâurological?. <i>BJU International</i> , 2015, 116, 314-316.	1.3	14
239	Nephroureterectomy surgery in the UK in 2012: British Association of Urological Surgeons (BAUS) Registry data. <i>BJU International</i> , 2015, 116, 780-790.	1.3	16
241	Functional and molecular characterization of cancer stem-like cells in bladder cancer: a potential signature for muscle-invasive tumors. <i>Oncotarget</i> , 2015, 6, 36185-36201.	0.8	34
242	One, 5 and 10 Year Net Survival Rates for Male and Female Bladder Cancer Patients; Why are they so Different?. <i>Journal of Women's Health Care</i> , 2015, 04, .	0.2	2
243	Urine microRNAs as biomarkers for bladder cancer: a diagnostic meta-analysis. <i>OncoTargets and Therapy</i> , 2015, 8, 2089.	1.0	13
244	The Role of Population-Based Observational Research in Bladder Cancer. <i>Bladder Cancer</i> , 2015, 1, 123-131.	0.2	1
245	Id Proteins Contribute to Tumor Development and Metastatic Colonization inÂa Model of Bladder Carcinogenesis. <i>Bladder Cancer</i> , 2015, 1, 159-170.	0.2	2
246	G Protein-Coupled Receptor 87 (GPR87) Promotes Cell Proliferation in Human Bladder Cancer Cells. <i>International Journal of Molecular Sciences</i> , 2015, 16, 24319-24331.	1.8	29
247	EZH2 in Bladder Cancer, a Promising Therapeutic Target. <i>International Journal of Molecular Sciences</i> , 2015, 16, 27107-27132.	1.8	57
248	p53 Status Correlates with the Risk of Recurrence in Non-Muscle Invasive Bladder Cancers Treated with Bacillus Calmetteâ€“GuÃ©rin: A Meta-Analysis. <i>PLoS ONE</i> , 2015, 10, e0119476.	1.1	15
249	Urinary Cytology in Bladder Cancer: Why is it Still Relevant?. <i>Urologia</i> , 2015, 82, 203-205.	0.3	10
250	Bladder Cancer in HIV-infected Adults: An Emerging Issue? Case-Reports and Systematic Review. <i>PLoS ONE</i> , 2015, 10, e0144237.	1.1	9
251	Identification of New Hub Genes Associated with Bladder Carcinoma via Bioinformatics Analysis. <i>Tumori</i> , 2015, 101, 117-122.	0.6	25

#	ARTICLE	IF	CITATIONS
252	Very Elderly (>80 Years), Frail Patients with Muscle-invasive Bladder Cancer and Comorbidities: Is Curative Irradiation Feasible?. <i>Tumori</i> , 2015, 101, 609-613.	0.6	6
253	Sacrocolpopexy with Polypropylene Tape as Valuable Surgical Modification during Cystectomy with Orthotopic Ileal Bladder: Functional Results. <i>BioMed Research International</i> , 2015, 2015, 1-4.	0.9	7
254	Occurrence uses and carcinogenicity of arylamines. <i>Frontiers in Bioscience - Elite</i> , 2015, 7, 367-393.	0.9	11
255	MicroRNA-218 inhibits bladder cancer cell proliferation, migration, and invasion by targeting BMI-1. <i>Tumor Biology</i> , 2015, 36, 8015-8023.	0.8	47
256	Preoperative lymphocyte-monocyte and platelet-lymphocyte ratios as predictors of overall survival in patients with bladder cancer undergoing radical cystectomy. <i>Tumor Biology</i> , 2015, 36, 8537-8543.	0.8	71
257	HAS3 underexpression as an indicator of poor prognosis in patients with urothelial carcinoma of the upper urinary tract and urinary bladder. <i>Tumor Biology</i> , 2015, 36, 5441-5450.	0.8	26
259	Expression of survivin in squamous cell carcinoma and transitional cell carcinoma of the urinary bladder: A comparative immunohistochemical study. <i>Korean Journal of Urology</i> , 2015, 56, 31.	1.2	8
260	Estimation of tissue optical properties between different grades and stages of urothelial carcinoma using diffuse reflectance spectroscopy. , 2015, , .		3
261	The effect of intravesical chemotherapy in the prevention of intravesical recurrence after nephroureterectomy for upper tract urothelial carcinoma: a meta-analysis. <i>Journal of Chemotherapy</i> , 2015, 27, 195-200.	0.7	13
262	ERK5 positively regulates cigarette smoke-induced urocytic epithelial-mesenchymal transition in SV-40 immortalized human urothelial cells. <i>Oncology Reports</i> , 2015, 34, 1581-1588.	1.2	15
263	Cell adhesion and urothelial bladder cancer: the role of cadherin switching and related phenomena. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2015, 370, 20140042.	1.8	46
264	Estrogen-like metabolites and DNA-adducts in urogenital schistosomiasis-associated bladder cancer. <i>Cancer Letters</i> , 2015, 359, 226-232.	3.2	57
265	Effect of Fermented Wheat Germ Extract with <i>Lactobacillus plantarum</i> dy-1 on HT-29 Cell Proliferation and Apoptosis. <i>Journal of Agricultural and Food Chemistry</i> , 2015, 63, 2449-2457.	2.4	36
266	Evidence from the â€œPROspective MulticEnTer Radical Cystectomy Series 2011 (PROMETRICS 2011)â€™ Study: How are Preoperative Patient Characteristics Associated with Urinary Diversion Type After Radical Cystectomy for Bladder Cancer?. <i>Annals of Surgical Oncology</i> , 2015, 22, 1032-1042.	0.7	33
267	Improving Selection Criteria for Early Cystectomy in High-Grade T1 Bladder Cancer: A Meta-Analysis of 15,215 Patients. <i>Journal of Clinical Oncology</i> , 2015, 33, 643-650.	0.8	165
268	Capillary zone electrophoresis onâ€line coupled to mass spectrometry: A perspective application for clinical proteomics. <i>Proteomics - Clinical Applications</i> , 2015, 9, 453-468.	0.8	43
269	Le cancer de la vessie: des perspectives thÃ©rapeutiques. <i>Actualites Pharmaceutiques</i> , 2015, 54, 30-35.	0.0	0
270	Urinary cytokines in patients treated with intravesical mitomycin-C with and without hyperthermia. <i>World Journal of Urology</i> , 2015, 33, 1411-1417.	1.2	10

#	ARTICLE	IF	CITATIONS
271	Akt phosphorylates Prohibitin 1 to mediate its mitochondrial localization and promote proliferation of bladder cancer cells. <i>Cell Death and Disease</i> , 2015, 6, e1660-e1660.	2.7	51
272	Tissue-Engineered Urinary Conduits. <i>Current Urology Reports</i> , 2015, 16, 8.	1.0	27
273	Noninvasive approaches for detecting and monitoring bladder cancer. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 283-294.	1.1	9
274	MicroRNA-576-3p Inhibits Proliferation in Bladder Cancer Cells by Targeting Cyclin D1. <i>Molecules and Cells</i> , 2015, 38, 130-137.	1.0	35
275	Efficacy of 18F-fluorodeoxyglucose-positron emission tomography/computed tomography in restaging muscle-invasive bladder cancer following radical cystectomy. <i>Experimental and Therapeutic Medicine</i> , 2015, 9, 717-724.	0.8	25
276	Pilot study of adoptive immunotherapy with sentinel node-derived T cells in muscle-invasive urinary bladder cancer. <i>Scandinavian Journal of Urology</i> , 2015, 49, 453-462.	0.6	13
277	High-Risk Nonmuscle Invasive Bladder Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2015, 29, 227-236.	0.9	3
278	A preoperative marker panel for the prediction of residual tumor and the decision making for repeat transurethral resection. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 165.e9-165.e14.	0.8	2
279	Intravesical chitosan/interleukin-12 immunotherapy induces tumor-specific systemic immunity against murine bladder cancer. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 689-696.	2.0	37
280	Health Related Quality of Life in Patients with Bladder Cancer: A Cross-Sectional Survey and Validation Study of the Hungarian Version of the Bladder Cancer Index. <i>Pathology and Oncology Research</i> , 2015, 21, 619-627.	0.9	17
281	Regulation of growth of human bladder cancer by miR-192. <i>Tumor Biology</i> , 2015, 36, 3791-3797.	0.8	36
282	Evaluation of the response chemotherapy for penile metastasis of bladder cancer using 18F-fluorodeoxyglucose-PET/CT. <i>International Journal of Surgery Case Reports</i> , 2015, 11, 33-36.	0.2	6
283	Are urothelial carcinomas of the upper urinary tract a distinct entity from urothelial carcinomas of the urinary bladder? Behavior of urothelial carcinoma after radical surgery with respect to anatomical location: a case control study. <i>BMC Cancer</i> , 2015, 15, 149.	1.1	15
284	Mir-135a enhances cellular proliferation through post-transcriptionally regulating PHLPP2 and FOXO1 in human bladder cancer. <i>Journal of Translational Medicine</i> , 2015, 13, 86.	1.8	52
285	A Rare Case of Upper Gastrointestinal Bleeding: Duodenal Metastasis of Transitional Cell Carcinoma Originating from Renal Pelvis. <i>Journal of Gastrointestinal Cancer</i> , 2015, 46, 325-326.	0.6	2
287	Dynamic contrast enhanced MRI-derived parameters are potential biomarkers of therapeutic response in bladder carcinoma. <i>European Journal of Radiology</i> , 2015, 84, 1023-1028.	1.2	27
288	11C-Choline PET/CT for Restaging of Bladder Cancer. <i>Clinical Nuclear Medicine</i> , 2015, 40, e1-e5.	0.7	23
289	Mucoadhesive polyacrylamide nanogel as a potential hydrophobic drug carrier for intravesical bladder cancer therapy. <i>European Journal of Pharmaceutical Sciences</i> , 2015, 72, 57-68.	1.9	49

#	ARTICLE	IF	CITATIONS
290	Reduced ING4 Expression Is Associated with the Malignancy of Human Bladder. <i>Urologia Internationalis</i> , 2015, 94, 464-471.	0.6	8
291	Pirarubicin induces an autophagic cytoprotective response through suppression of the mammalian target of rapamycin signaling pathway in human bladder cancer cells. <i>Biochemical and Biophysical Research Communications</i> , 2015, 460, 380-385.	1.0	13
292	Two Micrometer Continuous-Wave Thulium Laser Treating Primary Non-Muscle-Invasive Bladder Cancer: Is It Feasible? A Randomized Prospective Study. <i>Photomedicine and Laser Surgery</i> , 2015, 33, 517-523.	2.1	46
293	Early diagnosis of bladder cancer through the detection of urinary tyrosine-phosphorylated proteins. <i>British Journal of Cancer</i> , 2015, 113, 469-475.	2.9	12
294	A Comparative Analysis of the Influence of Gender, Pathway Delays, and Risk Factor Exposures on the Long-term Outcomes of Bladder Cancer. <i>European Urology Focus</i> , 2015, 1, 82-89.	1.6	10
295	Patterns, risks and outcomes of urethral recurrence after radical cystectomy for urothelial cancer; over 20 year single center experience. <i>International Journal of Surgery</i> , 2015, 13, 148-151.	1.1	22
297	Targeting the genetic alterations of the PI3K-akt-mTOR pathway: Its potential use in the treatment of bladder cancers. , 2015, 145, 1-18.		75
298	Current evidence of transurethral Ho:YAG and Tm:YAG treatment of bladder cancer: update 2014. <i>World Journal of Urology</i> , 2015, 33, 571-579.	1.2	47
299	Recurrence of Urothelial Bladder Carcinoma in the Colon Presenting as Hematochezia. <i>ACG Case Reports Journal</i> , 2016, 3, e99.	0.2	0
300	What should be the patient's preference regarding the choice of hospital in the case of radical cystectomy? Evaluation of early complications after open radical cystectomy in a medium and high volume setting in one hospital. <i>Patient Preference and Adherence</i> , 2016, Volume 10, 2181-2187.	0.8	5
301	Comparison of the combination therapy of bacillus Calmette-Guérin and mitomycin C with the monotherapy for non-muscle-invasive bladder cancer: a meta-analysis. <i>Neoplasma</i> , 2016, 63, 967-976.	0.7	3
302	Upper tract urothelial carcinoma: Paradigm shift towards nephron sparing management. <i>World Journal of Nephrology</i> , 2016, 5, 158.	0.8	33
303	Influence of gross specimen sampling on the incidence of incidental prostatic carcinoma in cystoprostatectomy specimens of patients with bladder carcinoma. <i>Polish Journal of Pathology</i> , 2016, 1, 8-12.	0.1	1
304	Integration of Gene Coexpression Network, GO Enrichment Analysis for Identification Gene Expression Signature of Invasive Bladder Carcinoma. <i>Transcriptomics: Open Access</i> , 2016, 04, .	0.2	3
305	Prognostic Impact of Thrombospondin-2 (THBS2) Overexpression on Patients with Urothelial Carcinomas of Upper Urinary Tracts and Bladders. <i>Journal of Cancer</i> , 2016, 7, 1541-1549.	1.2	44
306	Non-muscle invasive high grade urothelial carcinoma of the bladder. Which factors can influence understaging at the time of radical cystectomy?. <i>Archivio Italiano Di Urologia Andrologia</i> , 2016, 88, 13.	0.4	9
307	The hOGG1 Ser326Cys gene polymorphism and susceptibility for bladder cancer: a meta-analysis. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2016, 42, 883-896.	0.7	5
308	Nonmuscle invasive bladder cancer: a primer on immunotherapy. <i>Cancer Biology and Medicine</i> , 2016, 13, 194-205.	1.4	17

#	ARTICLE	IF	CITATIONS
309	ERCC1 C118T polymorphism has predictive value for platinum-based chemotherapy in patients with late-stage bladder cancer. <i>Genetics and Molecular Research</i> , 2016, 15, .	0.3	12
310	Comparison between standard and reduced volume radiotherapy in bladder preservation trimodality protocol for muscle-invasive bladder cancer patients. <i>Ecancermedicalsecience</i> , 2016, 10, 682.	0.6	8
311	Contrast enhanced ultrasound in urothelial carcinoma of urinary bladder: An underutilized staging and grading modality. <i>Central European Journal of Urology</i> , 2016, 69, 360-365.	0.2	8
312	Prognostic and Clinicopathological Significance of Downregulated p16 Expression in Patients with Bladder Cancer: A Systematic Review and Meta-Analysis. <i>Disease Markers</i> , 2016, 2016, 1-13.	0.6	19
313	Clinical Experiences of Korean Medicine Treatment against Urinary Bladder Cancer in General Practice. <i>Evidence-based Complementary and Alternative Medicine</i> , 2016, 2016, 1-7.	0.5	6
314	MiR-126 regulates proliferation and invasion in the bladder cancer BLS cell line by targeting the >PIK3R2-mediated PI3K/Akt signaling pathway. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 5181-5193.	1.0	36
315	Cutaneous invasion from sarcomatoid urothelial carcinoma: clinical and dermatopathologic features. <i>Anais Brasileiros De Dermatologia</i> , 2016, 91, 73-79.	0.5	1
316	Carcinogenicity allergenicity and lupus-inducibility of arylamines. <i>Frontiers in Bioscience - Elite</i> , 2016, 8, 29-39.	0.9	8
317	Risk of malignancy after augmentation cystoplasty: A systematic review. <i>Neurourology and Urodynamics</i> , 2016, 35, 675-682.	0.8	62
318	Exudative Retinal Detachment Reveals Metastatic Bladder Cancer. <i>Optometry and Vision Science</i> , 2016, 93, 549-554.	0.6	3
319	Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations. <i>Cancer</i> , 2016, 122, 702-711.	2.0	81
320	Audit of cytology of upper urinary tract. <i>Cytopathology</i> , 2016, 27, 369-373.	0.4	0
322	Suppression of SIPA-1 expression may reduce bladder cancer invasion and metastasis via the downregulation of E-cadherin and ZO-1. <i>Experimental and Therapeutic Medicine</i> , 2016, 11, 213-217.	0.8	4
323	Exploring glass as a novel method for hands-free data entry in flexible cystoscopy. , 2016, , .		4
324	mTOR inhibitors in urinary bladder cancer. <i>Tumor Biology</i> , 2016, 37, 11541-11551.	0.8	23
325	A new non-muscle-invasive bladder tumor-homing peptide identified by phage display in vivo. <i>Oncology Reports</i> , 2016, 36, 79-89.	1.2	15
326	Surgical technique for en bloc transurethral resection of bladder tumor with a Hybrid Knife®. <i>Actas Urológicas Españolas (English Edition)</i> , 2016, 40, 263-267.	0.2	7
327	Predictors for quality of life of bladder cancer patients with ileal conduit: A cross-sectional survey. <i>European Journal of Oncology Nursing</i> , 2016, 21, 168-173.	0.9	14

#	ARTICLE	IF	CITATIONS
328	MP88-14 ROLE OF STEROID HORMONE RECEPTORS IN FORMATION AND PROGRESSION OF BLADDER CARCINOMA: A CASE-CONTROL STUDY. <i>Journal of Urology</i> , 2016, 195, .	0.2	22
329	Expression Level of Urinary MicroRNA-146a-5p Is Increased in Patients With Bladder Cancer and Decreased in Those After Transurethral Resection. <i>Clinical Genitourinary Cancer</i> , 2016, 14, e493-e499.	0.9	53
330	Follow the Stream: Imaging of Urinary Diversions. <i>Radiographics</i> , 2016, 36, 688-709.	1.4	15
331	Chemotherapeutic potential of quercetin on human bladder cancer cells. <i>Journal of Environmental Science and Health - Part A Toxic/Hazardous Substances and Environmental Engineering</i> , 2016, 51, 776-781.	0.9	29
332	Urolithiasis following urinary diversion. <i>Urolithiasis</i> , 2016, 44, 383-388.	1.2	18
333	Somatic ERCC2 mutations are associated with a distinct genomic signature in urothelial tumors. <i>Nature Genetics</i> , 2016, 48, 600-606.	9.4	352
335	What factors are associated with unplanned return following transurethral resection of bladder tumor? An analysis of a large single institution's experience. <i>Scandinavian Journal of Urology</i> , 2016, 50, 370-373.	0.6	13
336	Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients. <i>BMC Cancer</i> , 2016, 16, 744.	1.1	94
337	Changes in oncological outcomes after radical nephroureterectomy in patients with upper urinary tract urothelial carcinoma treated in the last two decades: a retrospective analysis based on a multicenter collaborative study. <i>Japanese Journal of Clinical Oncology</i> , 2016, 46, 1148-1155.	0.6	16
338	Epigenetic events in male common urogenital organs cancer. <i>Journal of Cancer Research and Practice</i> , 2016, 3, 104-112.	0.2	0
339	Immune analysis of expression of IL-17 relative ligands and their receptors in bladder cancer: comparison with polyp and cystitis. <i>BMC Immunology</i> , 2016, 17, 36.	0.9	10
340	Intravesical therapy for non-muscle invasive bladder cancer: a network meta-analysis. <i>The Cochrane Library</i> , 2016, , .	1.5	0
341	The prognostic role of lymphovascular invasion in urothelial carcinoma of the bladder. <i>Nature Reviews Urology</i> , 2016, 13, 471-479.	1.9	79
342	A systematic review and meta-analysis of quality of life outcomes after radical cystectomy for bladder cancer. <i>Surgical Oncology</i> , 2016, 25, 281-297.	0.8	87
343	Proteome Profiling of Urinary Exosomes Identifies Alpha 1-Antitrypsin and H2B1K as Diagnostic and Prognostic Biomarkers for Urothelial Carcinoma. <i>Scientific Reports</i> , 2016, 6, 34446.	1.6	62
344	Screening differential circular RNA expression profiles reveals the regulatory role of circTCF25-miR-103a-3p/miR-107-CDK6 pathway in bladder carcinoma. <i>Scientific Reports</i> , 2016, 6, 30919.	1.6	379
345	Aurora-A in transitional cell carcinoma of urinary bladder. <i>Egyptian Journal of Pathology</i> , 2016, 36, 23-28.	0.0	0
346	A study of the prognostic and predictive role of HER-2 expression in bladder urothelial carcinoma. <i>Egyptian Journal of Pathology</i> , 2016, 36, 241-250.	0.0	0

#	ARTICLE	IF	CITATIONS
347	Elevated urinary urea by high-protein diet could be one of the inducements of bladder disorders. <i>Journal of Translational Medicine</i> , 2016, 14, 53.	1.8	12
348	Patient Satisfaction in a One-Stop Haematuria clinic and Urology Outpatients: A Comparison of Clinics. <i>International Journal of Urological Nursing</i> , 2016, 10, 127-136.	0.1	4
349	ImmunoCyt test compared to cytology in the diagnosis of bladder cancer: A meta-analysis. <i>Oncology Letters</i> , 2016, 12, 83-88.	0.8	54
350	BCAT1 overexpression is an indicator of poor prognosis in patients with urothelial carcinomas of the upper urinary tract and urinary bladder. <i>Histopathology</i> , 2016, 68, 520-532.	1.6	29
351	Sonic hedgehog (Shh) signaling promotes tumorigenicity and stemness via activation of epithelial-to-mesenchymal transition (EMT) in bladder cancer. <i>Molecular Carcinogenesis</i> , 2016, 55, 537-551.	1.3	100
352	Hypofractionated palliative radiotherapy for bladder cancer. <i>Supportive Care in Cancer</i> , 2016, 24, 181-186.	1.0	25
353	LDH-A promotes malignant progression via activation of epithelial-to-mesenchymal transition and conferring stemness in muscle-invasive bladder cancer. <i>Biochemical and Biophysical Research Communications</i> , 2016, 469, 985-992.	1.0	57
354	Genomic complexity of urothelial bladder cancer revealed in urinary cfDNA. <i>European Journal of Human Genetics</i> , 2016, 24, 1167-1174.	1.4	115
355	Técnica quirúrgica de la resección transuretral de tumor vesical en bloque con Hybrid Knife®. <i>Actas Urológicas Españolas</i> , 2016, 40, 263-267.	0.3	9
356	The PD-1/PD-L1 axis in the pathogenesis of urothelial bladder cancer and evaluating its potential as a therapeutic target. <i>Future Oncology</i> , 2016, 12, 595-600.	1.1	9
357	Chemotherapy for Muscle-Invasive Bladder Cancer. <i>Current Treatment Options in Oncology</i> , 2016, 17, 6.	1.3	19
358	Mg(II)-Catechin nanoparticles delivering siRNA targeting EIF5A2 inhibit bladder cancer cell growth in vitro and in vivo. <i>Biomaterials</i> , 2016, 81, 125-134.	5.7	43
359	Co-delivery of peptide-modified cisplatin and doxorubicin via mucoadhesive nanocapsules for potential synergistic intravesical chemotherapy of non-muscle-invasive bladder cancer. <i>European Journal of Pharmaceutical Sciences</i> , 2016, 84, 103-115.	1.9	29
360	Immunosensor for the ultrasensitive and quantitative detection of bladder cancer in point of care testing. <i>Biosensors and Bioelectronics</i> , 2016, 84, 126-132.	5.3	48
361	Open radical cystectomy: still the gold standard for muscle invasive bladder cancer. <i>World Journal of Urology</i> , 2016, 34, 33-39.	1.2	28
362	New Strategies in Bladder Cancer: A Second Coming for Immunotherapy. <i>Clinical Cancer Research</i> , 2016, 22, 793-801.	3.2	60
363	Down-regulation of Sphk2 suppresses bladder cancer progression. <i>Tumor Biology</i> , 2016, 37, 473-478.	0.8	13
364	Comparing RECIST with EORTC criteria in metastatic bladder cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 187-194.	1.2	12

#	ARTICLE	IF	CITATIONS
365	Outcome of Muscle-Invasive Urothelial Bladder Cancer After Radical Cystectomy. <i>Clinical Genitourinary Cancer</i> , 2016, 14, e43-e47.	0.9	17
367	Expression of CUL1 correlates with tumour grade and recurrence in urothelial carcinoma. <i>ANZ Journal of Surgery</i> , 2017, 87, 624-629.	0.3	3
368	Combination of Rapamycin and Resveratrol for Treatment of Bladder Cancer. <i>Journal of Cellular Physiology</i> , 2017, 232, 436-446.	2.0	41
369	ETS-1 oncoprotein expression is decreased in aggressive papillary transitional cell carcinoma of the urinary bladder: An immunohistochemical study. <i>African Journal of Urology</i> , 2017, 23, 120-125.	0.1	0
370	The immune infiltrate in prostate, bladder and testicular tumors: An old friend for new challenges. <i>Cancer Treatment Reviews</i> , 2017, 53, 138-145.	3.4	20
371	Metastatic Bladder Cancer. , 2017, , 177-198.		2
372	Intravesical Bacillus Calmette-Guérin with interferon-alpha versus intravesical Bacillus Calmette-Guérin for treating non-muscle-invasive bladder cancer. <i>The Cochrane Library</i> , 2017, 2017, CD012112.	1.5	26
373	Symptom Management for Bladder Cancer in Thailand. <i>International Journal of Urological Nursing</i> , 2017, 11, 82-89.	0.1	2
374	Targeted O-glycoproteomics explored increased sialylation and identified MUC16 as a poor prognosis biomarker in advanced stage bladder tumours. <i>Molecular Oncology</i> , 2017, 11, 895-912.	2.1	50
375	A platform for selective immuno-capture of cancer cells from urine. <i>Biosensors and Bioelectronics</i> , 2017, 96, 373-380.	5.3	48
376	ASP5878, a selective FGFR inhibitor, to treat FGFR3-dependent urothelial cancer with or without chemoresistance. <i>Cancer Science</i> , 2017, 108, 236-242.	1.7	19
378	Bladder cancer. <i>Nature Reviews Disease Primers</i> , 2017, 3, 17022.	18.1	590
379	Urothelial carcinoma involving the ureteral orifice: a clinicopathologic analysis of 93 cases. <i>Human Pathology</i> , 2017, 65, 101-106.	1.1	6
380	Transurethral en bloc resection of nonmuscle invasive bladder cancer. <i>Current Opinion in Urology</i> , 2017, 27, 182-190.	0.9	33
381	The association of rs710886 in lncRNA PCAT1 with bladder cancer risk in a Chinese population. <i>Gene</i> , 2017, 627, 226-232.	1.0	23
382	CCL21/CCR7 interaction promotes cellular migration and invasion via modulation of the MEK/ERK1/2 signaling pathway and correlates with lymphatic metastatic spread and poor prognosis in urinary bladder cancer. <i>International Journal of Oncology</i> , 2017, 51, 75-90.	1.4	42
383	Muscle invasive bladder cancer: Prognostic factors, follow-up and treatment of relapses. <i>Actas Urológicas Españolas (English Edition)</i> , 2017, 41, 352-358.	0.2	3
384	Significance of S100A8, S100A9 and calprotectin levels in bladder cancer. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2017, 77, 437-441.	0.6	32

#	ARTICLE	IF	CITATIONS
385	MicroRNA-608 inhibits proliferation of bladder cancer via AKT/FOXO3a signaling pathway. <i>Molecular Cancer</i> , 2017, 16, 96.	7.9	80
386	Recurrent bladder tumors after transurethral resection: Diagnostic yield of MDCT-virtual cystoscopy. <i>Egyptian Journal of Radiology and Nuclear Medicine</i> , 2017, 48, 509-517.	0.3	0
387	Carbonic anhydrase 2 is a novel invasion-associated factor in urinary bladder cancers. <i>Cancer Science</i> , 2017, 108, 331-337.	1.7	12
388	MicroRNA-218 Increases the Sensitivity of Bladder Cancer to Cisplatin by Targeting Glut1. <i>Cellular Physiology and Biochemistry</i> , 2017, 41, 921-932.	1.1	81
389	Identification of novel potential genetic predictors of urothelial bladder carcinoma susceptibility in Pakistani population. <i>Familial Cancer</i> , 2017, 16, 577-594.	0.9	9
390	A Discrete Isoperimetric Optimal Control Approach for BCG Immunotherapy in Superficial Bladder Cancer: Discussions on Results of Different Optimal Doses. <i>International Journal of Applied and Computational Mathematics</i> , 2017, 3, 1-18.	0.9	13
391	Urine cytology screening of French workers exposed to occupational urinary tract carcinogens: a prospective cohort study over a 20-year period. <i>BMJ Open</i> , 2017, 7, e016238.	0.8	0
392	Bioinformatics Meets Biomedicine: OncoFinder, a Quantitative Approach for Interrogating Molecular Pathways Using Gene Expression Data. <i>Methods in Molecular Biology</i> , 2017, 1613, 53-83.	0.4	62
394	Seeding of a high-grade papillary urothelial carcinoma of the bladder along a nephroureterostomy tract. <i>Radiology Case Reports</i> , 2017, 12, 542-545.	0.2	5
395	Laparoscopic radical cystectomy is feasible for the elderly with marginal cardiopulmonary function. <i>Urological Science</i> , 2017, , .	0.2	0
397	FGFR3, a marker suggestive of favorable prognosis in urothelial carcinoma. <i>Comparative Clinical Pathology</i> , 2017, 26, 1203-1208.	0.3	0
398	Association between MDM2-SNP309 and p53R72P polymorphisms and the risk of bladder cancer in the Mongolian population. <i>Molecular and Clinical Oncology</i> , 2017, 7, 412-420.	0.4	5
399	Hemostatic radiotherapy in advanced bladder cancer: a single-institution experience. <i>Journal of Radiation Oncology</i> , 2017, 6, 379-385.	0.7	1
400	LncRNA ZEB2-AS1 promotes bladder cancer cell proliferation and inhibits apoptosis by regulating miR-27b. <i>Biomedicine and Pharmacotherapy</i> , 2017, 96, 299-304.	2.5	51
401	Genomic Subtypes of Non-invasive Bladder Cancer with Distinct Metabolic Profile and Female Gender Bias in KDM6A Mutation Frequency. <i>Cancer Cell</i> , 2017, 32, 701-715.e7.	7.7	224
402	The Prognostic Value of Platelet-to-Lymphocyte Ratio in Urological Cancers: A Meta-Analysis. <i>Scientific Reports</i> , 2017, 7, 15387.	1.6	30
403	High dose-rate Intra-Operative Radiation Therapy During High Risk Genitourinary Surgery: Initial Observations and a Proposal for its Study in Bladder Cancer. <i>Bladder Cancer</i> , 2017, 3, 191-199.	0.2	4
404	Identification and functional analysis of risk-related microRNAs for the prognosis of patients with bladder urothelial carcinoma. <i>Oncology Letters</i> , 2017, 14, 7297-7303.	0.8	5

#	ARTICLE	IF	CITATIONS
405	Bufalin sensitizes human bladder carcinoma cells to TRAIL-mediated apoptosis. <i>Oncology Letters</i> , 2017, 14, 853-859.	0.8	18
406	An enhanced hTERT promoter-driven CRISPR/Cas9 system selectively inhibits the progression of bladder cancer cells. <i>Molecular BioSystems</i> , 2017, 13, 1713-1721.	2.9	10
407	Recurrent bladder carcinoma: clinical and prognostic role of 18 F-FDG PET/CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 224-233.	3.3	39
408	Cáncer vesical infiltrante: factores pronósticos, seguimiento y tratamiento de las recidivas. <i>Actas Urológicas Españolas</i> , 2017, 41, 352-358.	0.3	5
409	Expression of Epidermal Growth Factor Receptor and Transforming Growth Factor Alpha in Cancer Bladder: Schistosomal and Non-Schistosomal. <i>Current Urology</i> , 2017, 9, 192-201.	0.4	9
410	Bladder Cancer Recovery Pathways: A Systematic Review. <i>Bladder Cancer</i> , 2017, 3, 269-281.	0.2	14
411	miR-5195-3p Inhibits Proliferation and Invasion of Human Bladder Cancer Cells by Directly Targeting Oncogene KLF5. <i>Oncology Research</i> , 2017, 25, 1081-1087.	0.6	39
412	The Inhibitory Effect of PDIA6 Downregulation on Bladder Cancer Cell Proliferation and Invasion. <i>Oncology Research</i> , 2017, 25, 587-593.	0.6	30
413	Occupations and the Risk of Bladder Cancer in Yazd Province: A Case-Control Study. <i>International Journal of Occupational and Environmental Medicine</i> , 2017, 8, 191-198.	4.1	5
414	Microdevices for Non-Invasive Detection of Bladder Cancer. <i>Chemosensors</i> , 2017, 5, 30.	1.8	8
415	Intravesical Gemcitabine versus Intravesical Bacillus Calmette-Guérin for the Treatment of Non-Muscle Invasive Bladder Cancer: An Evaluation of Efficacy and Toxicity. <i>Frontiers in Oncology</i> , 2017, 7, 260.	1.3	28
416	Stromal antigen 2 functions as a tumor suppressor in bladder cancer cells. <i>Oncology Reports</i> , 2017, 38, 917-925.	1.2	5
417	Systemic Chemotherapy in Muscle Invasive and Metastatic Bladder Cancer: Present and Future. <i>Urologia</i> , 2017, 84, 130-141.	0.3	8
418	IGF1R activation and the in vitro antiproliferative efficacy of IGF1R inhibitor are inversely correlated with IGFBP5 expression in bladder cancer. <i>BMC Cancer</i> , 2017, 17, 636.	1.1	18
419	Retroperitoneal laparoscopic partial nephrectomy with segmental renal artery clamping for cancer of the left upper calyx: a case report. <i>BMC Urology</i> , 2017, 17, 73.	0.6	1
420	Ureteral orifice involvement by urothelial carcinoma: long term oncologic and functional outcomes. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2017, 43, 1052-1059.	0.7	9
421	Prognostic role of matrix metalloproteinases in bladder carcinoma: a systematic review and meta-analysis. <i>Oncotarget</i> , 2017, 8, 32309-32321.	0.8	30
422	Association between obesity and bladder cancer recurrence: A meta-analysis. <i>Clinica Chimica Acta</i> , 2018, 480, 41-46.	0.5	28

#	ARTICLE	IF	CITATIONS
423	Transurethral resection of bladder cancer on the lateral bladder wall without obturator nerve block: extent of adductor spasms using the monopolar versus bipolar technique—a prospective randomised study. <i>World Journal of Urology</i> , 2018, 36, 1085-1091.	1.2	11
424	Prognostic value of ki67 in BCG-treated non-muscle invasive bladder cancer: a meta-analysis and systematic review. <i>BMJ Open</i> , 2018, 8, e019635.	0.8	18
425	Knowledge of smoking as a risk factor for disease among urology clinic patients in Australia. <i>World Journal of Urology</i> , 2018, 36, 1219-1224.	1.2	8
426	MicroRNA-411 Downregulation Enhances Tumor Growth by Upregulating MLLT11 Expression in Human Bladder Cancer. <i>Molecular Therapy - Nucleic Acids</i> , 2018, 11, 312-322.	2.3	39
427	Inhibition of E-cadherin expression by lnc-RNA H19 to facilitate bladder cancer metastasis. <i>Cancer Biomarkers</i> , 2018, 22, 275-281.	0.8	20
428	Overexpression of COX2 indicates poor survival in urothelial bladder cancer. <i>Annals of Diagnostic Pathology</i> , 2018, 34, 50-55.	0.6	22
429	Bladder resident macrophages: Mucosal sentinels. <i>Cellular Immunology</i> , 2018, 330, 136-141.	1.4	27
430	Folic Acid Modified Polymeric Micelles for Intravesical Instilled Chemotherapy. <i>Chinese Journal of Polymer Science (English Edition)</i> , 2018, 36, 479-487.	2.0	6
432	Detection of urothelial carcinoma, upper tract urothelial carcinoma, bladder carcinoma, and urothelial carcinoma with gross hematuria using selected urine-DNA methylation biomarkers: A prospective, single-center study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 342.e15-342.e23.	0.8	31
433	Prognostic significance of epithelial-mesenchymal transition phenotypes in upper urinary tract urothelial carcinoma. <i>Pathology Research and Practice</i> , 2018, 214, 547-554.	1.0	9
434	Long non-coding RNA HNF1A-AS1 promotes cell viability and migration in human bladder cancer. <i>Oncology Letters</i> , 2018, 15, 4535-4540.	0.8	12
435	Avelumab for the treatment of urothelial cancer. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 421-429.	1.1	9
436	A Novel Urine-Based Assay for Bladder Cancer Diagnosis: Multi-Institutional Validation Study. <i>European Urology Focus</i> , 2018, 4, 388-394.	1.6	19
438	CYP1A1 expression and organochlorine pesticides level in the etiology of bladder cancer in North Indian population. <i>Human and Experimental Toxicology</i> , 2018, 37, 817-826.	1.1	7
439	A Novel Presentation of Bladder Mass. <i>Female Pelvic Medicine and Reconstructive Surgery</i> , 2018, 24, e29-e31.	0.6	0
440	A 3' untranslated region polymorphism rs2304277 in the DNA repair pathway gene OGG1 is a novel risk modulator for urothelial bladder carcinoma. <i>Annals of Human Genetics</i> , 2018, 82, 74-87.	0.3	3
441	Circular RNA hsa_circ_0003221 (circPTK2) promotes the proliferation and migration of bladder cancer cells. <i>Journal of Cellular Biochemistry</i> , 2018, 119, 3317-3325.	1.2	70
442	Evaluation of upper tract urothelial carcinomas by contrast-enhanced ultrasound. <i>Radiologia</i> , 2018, 60, 496-503.	0.3	0

#	ARTICLE	IF	CITATIONS
443	Rapid ultrasound for shock and hypotension reveals an unexpected finding. <i>Visual Journal of Emergency Medicine</i> , 2018, 13, 96-97.	0.0	0
444	MicroRNA-539 inhibits the proliferation and invasion of bladder cancer cells by regulating IGF1R. <i>Molecular Medicine Reports</i> , 2018, 17, 4917-4924.	1.1	8
445	How to assess and improve health-related quality of life in bladder cancer patients. <i>Translational Andrology and Urology</i> , 2018, 7, S77-S80.	0.6	4
446	Evaluation of lymph node status in patients with urothelial carcinoma—still in search of the perfect imaging modality: a systematic review. <i>Translational Andrology and Urology</i> , 2018, 7, 783-803.	0.6	13
447	Association of CYP2E1 gene polymorphisms with bladder cancer risk. <i>Medicine (United States)</i> , 2018, 97, e11910.	0.4	19
448	miRNA-373 promotes urinary bladder cancer cell proliferation, migration and invasion through upregulating epidermal growth factor receptor. <i>Experimental and Therapeutic Medicine</i> , 2018, 17, 1190-1195.	0.8	10
449	Socio-economic impact of BCG shortage. <i>European Urology Supplements</i> , 2018, 17, 60-62.	0.1	2
450	The Use of Polymer Chitosan in Intravesical Treatment of Urinary Bladder Cancer and Infections. <i>Polymers</i> , 2018, 10, 265.	2.0	10
451	Valoración del carcinoma urotelial de vías superiores mediante ecografía con contraste. <i>Radiología</i> , 2018, 60, 496-503.	0.3	0
452	Ex vivo assays to predict enhanced chemosensitization by hyperthermia in urothelial cancer of the bladder. <i>PLoS ONE</i> , 2018, 13, e0209101.	1.1	7
453	Paper-based immunosensor utilizing dielectrophoretic trapping of microprobes for quantitative and label free detection using electrochemical impedance spectroscopy. <i>Biomicrofluidics</i> , 2018, 12, 064102.	1.2	5
454	Bladder Cancer—Specific Nuclear Matrix Proteins-4 May Be a Potential Biomarker for Non-Muscle-Invasive Bladder Cancer Detection. <i>Disease Markers</i> , 2018, 2018, 1-6.	0.6	4
455	<i>Urothelial Cancer</i> , 2018, , 523-529.		0
456	Performance of the Bladder EpiCheck, Methylation Test for Patients Under Surveillance for Non-muscle-invasive Bladder Cancer: Results of a Multicenter, Prospective, Blinded Clinical Trial. <i>European Urology Oncology</i> , 2018, 1, 307-313.	2.6	92
457	Exosome-transmitted long non-coding RNA PTENP1 suppresses bladder cancer progression. <i>Molecular Cancer</i> , 2018, 17, 143.	7.9	217
458	Robot assisted radical cystectomy with totally intracorporeal urinary diversion: initial, single-surgeon's experience after a modified modular training. <i>Minerva Urology and Nephrology</i> , 2018, 70, 193-201.	1.3	16
459	miR-145-5p inhibits the proliferation and migration of bladder cancer cells by targeting TAGLN2. <i>Oncology Letters</i> , 2018, 16, 6355-6360.	0.8	56
460	National Cancer Database Comparison of Radical Cystectomy vs Chemoradiotherapy for Muscle-Invasive Bladder Cancer: Implications of Using Clinical vs Pathologic Staging. <i>Cancer Medicine</i> , 2018, 7, 5370-5381.	1.3	14

#	ARTICLE	IF	CITATIONS
461	A Rare Presentation of Cardiac Tamponade from Metastatic Urothelial Carcinoma of the Bladder. Case Reports in Cardiology, 2018, 2018, 1-4.	0.1	2
462	Differences in Pathologic Results of Repeat Transurethral Resection of Bladder Tumor (TURBT) according to Institution Performing the Initial TURBT: Comparative Analyses between Referred and Nonreferred Group. BioMed Research International, 2018, 2018, 1-7.	0.9	6
463	Functional analysis of gene expression profilingâ€based prediction in bladder cancer. Oncology Letters, 2018, 15, 8417-8423.	0.8	3
465	A placebo-controlled efficacy study of the intravesical immunomodulators TMX-101 and TMX-202 in an orthotopic bladder cancer rat model. World Journal of Urology, 2018, 36, 1719-1725.	1.2	7
466	Knockdown of long non-coding RNA linc00511 suppresses proliferation and promotes apoptosis of bladder cancer cells via suppressing Wnt/ β -catenin signaling pathway. Bioscience Reports, 2018, 38, .	1.1	38
467	Glyoxalases in Urological Malignancies. International Journal of Molecular Sciences, 2018, 19, 415.	1.8	45
468	Incidence of bladder cancer in Benghazi, Libya over the past three decades. Scientific Reports, 2018, 8, 10822.	1.6	4
469	Genomic Profiling of Two Histologically Distinct Rare Urothelial Cancers in a Clinical Setting to Identify Potential Therapeutic Options for Treatment and Management of Disease. Case Reports in Oncology, 2018, 11, 196-205.	0.3	6
470	Safety and efficacy of tamsulosin as second line treatment for patients with recurrent bladder cancer. BMC Cancer, 2018, 18, 194.	1.1	18
471	Epidemiology and Sociocultural Differences for Bladder Cancer. , 2018, , 1-11.		0
472	Lumbrokinase/paclitaxel nanoparticle complex: potential therapeutic applications in bladder cancer. International Journal of Nanomedicine, 2018, Volume 13, 3625-3640.	3.3	14
473	Bladder cancer in nonagenarians: a multicentre study of 123 patients. BJU International, 2018, 122, 1010-1015.	1.3	7
475	ICUD-SIU International Consultation on Bladder Cancer 2017: management of non-muscle invasive bladder cancer. World Journal of Urology, 2019, 37, 51-60.	1.2	31
476	Impact of perioperative blood transfusions on clinical outcomes in patients undergoing surgery for major urologic malignancies. Therapeutic Advances in Urology, 2019, 11, 175628721986805.	0.9	3
477	Epidemiology and Sociocultural Differences for Bladder Cancer. , 2019, , 291-301.		1
478	A population-based cohort study examining the association of documented bladder diverticulum and bladder cancer risk in urology patients. PLoS ONE, 2019, 14, e0222875.	1.1	11
479	Comparison of Preoperative Neutrophil-Lymphocyte and Platelet-Lymphocyte Ratios in Bladder Cancer Patients Undergoing Radical Cystectomy. BioMed Research International, 2019, 2019, 1-7.	0.9	7
480	Bidirectional expression of Toll-like receptor 7 gene in urinary bladder cancer and urinary tract infection of Iraqi patients. Gene Reports, 2019, 17, 100491.	0.4	0

#	ARTICLE	IF	CITATIONS
481	CD44 splice variant (CD44v3) promotes progression of urothelial carcinoma of bladder through Akt/ERK/STAT3 pathways: novel therapeutic approach. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 2649-2661.	1.2	29
482	Squamous cell carcinoma of the bladder: poor response to neoadjuvant chemotherapy. <i>International Journal of Clinical Oncology</i> , 2019, 24, 706-711.	1.0	28
483	Low-keV virtual monoenergetic imaging reconstructions of excretory phase spectral dual-energy CT in patients with urothelial carcinoma: A feasibility study. <i>European Journal of Radiology</i> , 2019, 116, 135-143.	1.2	16
484	The association between coffee consumption and bladder cancer in the bladder cancer epidemiology and nutritional determinants (BLEND) international pooled study. <i>Cancer Causes and Control</i> , 2019, 30, 859-870.	0.8	10
485	Quality Control Indicators for Transurethral Resection of Non-Muscle-Invasive Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e784-e792.	0.9	40
486	Tumor Budding: Prognostic Value in Muscle-invasive Bladder Cancer. <i>Urology</i> , 2019, 130, 93-98.	0.5	18
487	Urinary Calprotectin loses specificity as tumour marker due to sterile leukocyturia associated with bladder cancer. <i>PLoS ONE</i> , 2019, 14, e0213549.	1.1	4
488	Delays in radical cystectomy for muscle-invasive bladder cancer. <i>Cancer</i> , 2019, 125, 2011-2017.	2.0	44
489	Comparison of Outcomes between Standard and Palliative Management for High Grade Non-Muscle Invasive Bladder Cancer in Patients Older than 85 Years. <i>Urologia Internationalis</i> , 2019, 102, 277-283.	0.6	6
490	lncRNA CASC11 promotes cancer cell proliferation in bladder cancer through miRNA-150. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 13487-13493.	1.2	92
491	lncRNA TUG1 Promotes Cisplatin Resistance by Regulating CCND2 via Epigenetically Silencing miR-194-5p in Bladder Cancer. <i>Molecular Therapy - Nucleic Acids</i> , 2019, 16, 257-271.	2.3	79
492	Overall survival, costs, and healthcare resource use by line of therapy in Medicare patients with newly diagnosed metastatic urothelial carcinoma. <i>Journal of Medical Economics</i> , 2019, 22, 662-670.	1.0	28
493	Expression profiles analysis identifies the values of carcinogenesis and the prognostic prediction of three genes in adrenocortical carcinoma. <i>Oncology Reports</i> , 2019, 41, 2440-2452.	1.2	10
494	miR-3687 Overexpression Promotes Bladder Cancer Cell Growth by Inhibiting the Negative Effect of FOXP1 on Cyclin E2 Transcription. <i>Molecular Therapy</i> , 2019, 27, 1028-1038.	3.7	14
495	Prognostic value of differentially methylated gene profiles in bladder cancer. <i>Journal of Cellular Physiology</i> , 2019, 234, 18763-18772.	2.0	11
496	Magnetic multiwalled carbon nanotubes with controlled release of epirubicin: an intravesical instillation system for bladder cancer. <i>International Journal of Nanomedicine</i> , 2019, Volume 14, 1241-1254.	3.3	43
497	Recent advances in the metabolomic study of bladder cancer. <i>Expert Review of Proteomics</i> , 2019, 16, 315-324.	1.3	28
498	Global Transcriptional Analysis of Nontransformed Human Intestinal Epithelial Cells (FHs 74 Int) after Exposure to Selected Drinking Water Disinfection By-Products. <i>Environmental Health Perspectives</i> , 2019, 127, 117006.	2.8	21

#	ARTICLE	IF	CITATIONS
499	A Rare Case of Granulomatous Pneumonitis Due to Intravesical BCG for Bladder Cancer. <i>Acta Medica Portuguesa</i> , 2019, 32, 316.	0.2	5
500	Intrinsic Molecular Subclassification of Urothelial Carcinoma of the Bladder: Are We Finally there?. <i>Advances in Anatomic Pathology</i> , 2019, 26, 251-256.	2.4	9
501	Development of a Prospective Data Registry System for Non-muscle-Invasive Bladder Cancer Patients Incorporated in the Electronic Patient File System. <i>Frontiers in Oncology</i> , 2019, 9, 1402.	1.3	3
502	The utility of upper urinary tract urine cytology before and after application of the Paris system. <i>Diagnostic Cytopathology</i> , 2019, 47, 421-427.	0.5	19
503	Comparison of Different Treatment Schedules of Mitomycin C Intravesical Instillation in High-Risk Superficial Bladder Cancer Patients. <i>Aktuelle Urologie</i> , 2019, 50, 292-297.	0.3	1
504	Biological function and molecular mechanism of piRNA in cancer. <i>Practical Laboratory Medicine</i> , 2019, 13, e00113.	0.6	43
505	Incidental Gynecologic Tract Neoplasms in Women Undergoing Anterior Pelvic Exenteration for Urothelial Carcinoma. <i>International Journal of Gynecological Pathology</i> , 2019, 38, 97-102.	0.9	3
507	MiR-125b-5p suppresses the bladder cancer progression via targeting HK2 and suppressing PI3K/AKT pathway. <i>Human Cell</i> , 2020, 33, 185-194.	1.2	61
508	Comparison of standard vs. palliative management for bladder cancer in patients older than 85 years: multicenter study of 317 de novo tumors. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 40.e9-40.e15.	0.8	6
509	Robot-assisted vs open radical cystectomy for bladder cancer in adults. <i>BJU International</i> , 2020, 125, 765-779.	1.3	19
510	An EMT-related gene signature for the prognosis of human bladder cancer. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 605-617.	1.6	132
511	The global burden of urinary bladder cancer: an update. <i>World Journal of Urology</i> , 2020, 38, 1895-1904.	1.2	504
512	Bladder Cancer Stage Development, 2004-2014 in Europe Compared With the United States: Analysis of European Population-based Cancer Registries, the United States SEER Database, and a Large Tertiary Institutional Cohort. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 162-170.e4.	0.9	12
513	Apaziquone for Nonmuscle Invasive Bladder Cancer. <i>Urologic Clinics of North America</i> , 2020, 47, 73-82.	0.8	5
514	Comparative Application of Different Substaging Techniques for Non-Muscle Invasive Urothelial Carcinoma. <i>Pathology and Oncology Research</i> , 2020, 26, 1823-1831.	0.9	1
515	Bacillus Calmette-Guérin immunotherapy for bladder cancer: a review of immunological aspects, clinical effects and BCG infections. <i>Apmis</i> , 2020, 128, 92-103.	0.9	64
516	Adaptive Immune Resistance to Intravesical BCG in Non-Muscle Invasive Bladder Cancer: Implications for Prospective BCG-Unresponsive Trials. <i>Clinical Cancer Research</i> , 2020, 26, 882-891.	3.2	98
517	<p>>Circular RNAs and Bladder Cancer</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 9573-9586.	1.0	11

#	ARTICLE	IF	CITATIONS
518	Cationic amphiphilic drugs as potential anticancer therapy for bladder cancer. <i>Molecular Oncology</i> , 2020, 14, 3121-3134.	2.1	6
519	miR-211-5p is downregulated and a prognostic marker in bladder cancer. <i>Journal of Gene Medicine</i> , 2020, 22, e3270.	1.4	12
520	The protoapigenone analog WYC0209 targets CD133+ cells: A potential adjuvant agent against cancer stem cells in urothelial cancer therapy. <i>Toxicology and Applied Pharmacology</i> , 2020, 402, 115129.	1.3	4
521	Survival Outcomes of Early versus Deferred Cystectomy for High-Grade Non-Muscle-Invasive Bladder Cancer: A Systematic Review. <i>Current Urology</i> , 2020, 14, 66-73.	0.4	15
522	Non coding RNAs as the critical factors in chemo resistance of bladder tumor cells. <i>Diagnostic Pathology</i> , 2020, 15, 136.	0.9	20
523	LncRNA DDX11-AS1: a novel oncogene in human cancer. <i>Human Cell</i> , 2020, 33, 946-953.	1.2	29
524	Grain and dietary fiber intake and bladder cancer risk: a pooled analysis of prospective cohort studies. <i>American Journal of Clinical Nutrition</i> , 2020, 112, 1252-1266.	2.2	21
525	Evolution of Urothelial Bladder Cancer in the Context of Molecular Classifications. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5670.	1.8	49
526	Human epidermal growth factor receptor 2 (<i>HER2</i>) gene amplification in non-muscle invasive urothelial bladder cancers: Identification of patients for targeted therapy. <i>Arab Journal of Urology Arab Association of Urology</i> , 2020, 18, 267-272.	0.7	7
527	Mutational Landscape and Environmental Effects in Bladder Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6072.	1.8	30
528	Survival rate of patients with bladder cancer and its related factors in Kurdistan Province (2013-2018): a population-based study. <i>BMC Urology</i> , 2020, 20, 195.	0.6	6
529	The Impact of a New Interleukin-2-Based Immunotherapy Candidate on Urothelial Cells to Support Use for Intravesical Drug Delivery. <i>Life</i> , 2020, 10, 231.	1.1	3
530	Comparison of urine cytology diagnostic reports before and after the implementation of the Paris System classification system in China. <i>Cytopathology</i> , 2020, 31, 457-462.	0.4	4
531	Thrombomodulin Expression in Bladder Cancer Tissue and Its Association with Prognosis and Patient Survival. <i>Research and Reports in Urology</i> , 2020, Volume 12, 157-165.	0.6	3
532	LncRNA <i>DDX11-AS1</i> Promotes Bladder Cancer Occurrence Via Protecting <i>LAMB3</i> from Downregulation by Sponging <i>miR-2355-5p</i> . <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2020, 35, 319-328.	0.7	21
533	Evaluation of Vesical Imaging-Reporting and Data System (VI-RADS) scoring system in predicting muscle invasion of bladder cancer. <i>Translational Andrology and Urology</i> , 2020, 9, 445-451.	0.6	35
534	The current role of PET/CT in urological malignancies. <i>Clinical and Translational Imaging</i> , 2020, 8, 313-347.	1.1	2
535	TERT Promoter Mutation as a Potential Predictive Biomarker in BCG-Treated Bladder Cancer Patients. <i>International Journal of Molecular Sciences</i> , 2020, 21, 947.	1.8	19

#	ARTICLE	IF	CITATIONS
536	<p>miRNAs: A Promising Target in the Chemoresistance of Bladder Cancer</p>. OncoTargets and Therapy, 2019, Volume 12, 11805-11816.	1.0	31
537	Epigenetic alterations in female urogenital organs cancer: Premise, properties, and perspectives. Scientific African, 2020, 7, e00318.	0.7	0
538	Fibroblasts in urothelial bladder cancer define stroma phenotypes that are associated with clinical outcome. Scientific Reports, 2020, 10, 281.	1.6	42
539	Coffee consumption and risk of bladder cancer: a pooled analysis of 501,604 participants from 12 cohort studies in the BLadder Cancer Epidemiology and Nutritional Determinants (BLEND) international study. European Journal of Epidemiology, 2020, 35, 523-535.	2.5	14
540	A Specific Blood Signature Reveals Higher Levels of S100A12: A Potential Bladder Cancer Diagnostic Biomarker Along With Urinary Engrailed-2 Protein Detection. Frontiers in Oncology, 2020, 9, 1484.	1.3	6
541	Lifestyle associated factors and risk of urinary bladder cancer: A prospective cohort study from Norway. Cancer Medicine, 2020, 9, 4420-4432.	1.3	7
542	Antibiotic prophylaxis in transurethral resection of bladder tumours: study protocol for a systematic review and meta-analysis. Systematic Reviews, 2020, 9, 89.	2.5	0
543	Structure-based drug design of 1,3,5-triazine and pyrimidine derivatives as novel FGFR3 inhibitors with high selectivity over VEGFR2. Bioorganic and Medicinal Chemistry, 2020, 28, 115453.	1.4	16
544	Perioperative outcomes and safety of robotic vs open cystectomy: a systematic review and meta-analysis of 12,640 cases. World Journal of Urology, 2021, 39, 1733-1746.	1.2	8
546	Non-Muscular Invasive Bladder Cancer: Re-envisioning Therapeutic Journey from Traditional to Regenerative Interventions. , 2021, 12, 868.		14
547	A multi-institutional retrospective study of hyperthermic plus intravesical chemotherapy versus intravesical chemotherapy treatment alone in intermediate and high risk nonmuscle-invasive bladder cancer. Cancer Biology and Medicine, 2021, 18, 308-317.	1.4	8
548	Contemporary Outcomes of Open Radical Cystectomy: a 5-Year Experience from a Tertiary Care Center. Indian Journal of Surgical Oncology, 2021, 12, 86-93.	0.3	2
549	The aging-related risk signature in colorectal cancer. Aging, 2021, 13, 7330-7349.	1.4	49
550	TRICHINOSIS AS A FACTOR DETERMINING THE CHANGE IN THE EXPRESSION OF PROTOONCOGENES AND SUPPRESSOR GENE IN EXPERIMENT. Å½urnal Grodnenskogo Gosudarstvennogo Medicinskogo Universiteta, 2021, 19, 91-95.	0.0	0
552	Preclinical analysis of novel prognostic transcription factors and immuneâ€related gene signatures for bladder cancer via TCGAâ€based bioinformatic analysis. Oncology Letters, 2021, 21, 344.	0.8	3
553	Vegetable intake and the risk of bladder cancer in the BLadder Cancer Epidemiology and Nutritional Determinants (BLEND) international study. BMC Medicine, 2021, 19, 56.	2.3	17
554	Discovery of Novel Protein Biomarkers in Urine for Diagnosis of Urothelial Cancer Using iTRAQ Proteomics. Journal of Proteome Research, 2021, 20, 2953-2963.	1.8	18
555	Rapidly Progressing Urothelial Carcinoma Due to a Rare TP53 (p.Arg110Pro) Mutation: A Case Report and Review of the Literature. Research and Reports in Urology, 2021, Volume 13, 181-184.	0.6	1

#	ARTICLE	IF	CITATIONS
556	Metastatic Adenocarcinoma of the Bladder Presenting as Malignant Pleural Effusion: A Rare Presentation of Bladder Adenocarcinoma. <i>Cureus</i> , 2021, 13, e15152.	0.2	2
557	Ascariasis as a factor changing the expression levels of BIRC-5, GLI, VEGF and TP53 suppressor gene in tissue biopsies in rats during the reproduction of experimental C6 glioma. <i>Problemy Zdorov'ia i Ākologii</i> , 2021, , 109-114.	0.0	0
558	Long Noncoding RNA SNHG1 Activates Autophagy and Promotes Cell Invasion in Bladder Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 660551.	1.3	16
559	Vitamin D and Vitamin D-binding protein and risk of bladder cancer: A nested case-control study in the Norwegian Janus Serum Bank Cohort. <i>Cancer Medicine</i> , 2021, 10, 4107-4116.	1.3	4
560	Transcriptomic Analysis of Gene Networks Regulated by U11 Small Nuclear RNA in Bladder Cancer. <i>Frontiers in Genetics</i> , 2021, 12, 695597.	1.1	3
561	How Assessment-Schedule Matching Limits Bias When Comparing Progression-Free Survival in Single-Arm Studies: An Application in Second-Line Urothelial Carcinoma Treatments. <i>Value in Health</i> , 2021, 24, 1137-1144.	0.1	2
563	Clinicopathological study of urothelial neoplasms in urinary bladder with special reference to expression of Her2/neu and Ki-67 in malignant lesions. <i>Indian Journal of Pathology and Oncology</i> , 2021, 8, 378-385.	0.1	1
564	Bladder mesenchymal stromal cell-derived exosomal miRNA-217 modulates bladder cancer cell survival through Hippo-YAP pathway. <i>Inflammation Research</i> , 2021, 70, 959-969.	1.6	8
565	Silencing circ-BIRC6 inhibits the proliferation, invasion, migration and epithelial-mesenchymal transition of bladder cancer cells by targeting the miR-495/3p/XBP1 signaling axis. <i>Molecular Medicine Reports</i> , 2021, 24, .	1.1	10
566	Potential contribution of benzodiazepine abuse in the development of a bladder sarcomatoid carcinoma: A case report. <i>Molecular and Clinical Oncology</i> , 2021, 15, 231.	0.4	2
567	The Emerging Functions of Circular RNAs in Bladder Cancer. <i>Cancers</i> , 2021, 13, 4618.	1.7	9
568	Advances and Controversies With Checkpoint Inhibitors in Bladder Cancer. <i>Clinical Medicine Insights: Oncology</i> , 2021, 15, 117955492110449.	0.6	18
569	Role of immunotherapy in bladder cancer. <i>Cancer Treatment and Research Communications</i> , 2021, 26, 100296.	0.7	41
570	Robotic versus open radical cystectomy for bladder cancer in adults. <i>The Cochrane Library</i> , 2019, 2019, CD011903.	1.5	63
571	Liver Metastases from Ureteral and Bladder Cancer. , 2015, , 175-182.		2
572	Clinical Aspects of Urea Transporters. <i>Sub-Cellular Biochemistry</i> , 2014, 73, 179-191.	1.0	3
573	Follow-up in non-muscle invasive bladder cancer: facts and future. <i>World Journal of Urology</i> , 2021, 39, 4047-4053.	1.2	21
574	Vitamin E consumption and the risk of bladder cancer. <i>International Journal for Vitamin and Nutrition Research</i> , 2019, 89, 168-175.	0.6	13

#	ARTICLE	IF	CITATIONS
575	Predictive value of β -catenin in bladder cancer: a systematic review and meta-analysis. Bioscience Reports, 2020, 40, .	1.1	6
576	Complications of intravesical BCG therapy in non-muscle invasive bladder cancer: our tertiary care centre experience. African Journal of Urology, 2020, 26, .	0.1	6
577	Preoperative Anemia as a Simple Prognostic Factor in Patients with Urinary Bladder Cancer. Medical Science Monitor, 2017, 23, 3528-3535.	0.5	15
578	Expression of RFC/SLC19A1 is Associated with Tumor Type in Bladder Cancer Patients. PLoS ONE, 2011, 6, e21820.	1.1	13
579	Ultrasound-Guided Intramural Inoculation of Orthotopic Bladder Cancer Xenografts: A Novel High-Precision Approach. PLoS ONE, 2013, 8, e59536.	1.1	43
580	The Impact of the Receptor of Hyaluronan-Mediated Motility (RHAMM) on Human Urothelial Transitional Cell Cancer of the Bladder. PLoS ONE, 2013, 8, e75681.	1.1	32
581	The Expression Patterns of p53 and p16 and an Analysis of a Possible Role of HPV in Primary Adenocarcinoma of the Urinary Bladder. PLoS ONE, 2014, 9, e95724.	1.1	18
582	Analysis of Tissue and Serum MicroRNA Expression in Patients with Upper Urinary Tract Urothelial Cancer. PLoS ONE, 2015, 10, e0117284.	1.1	42
583	Opium and bladder cancer: A systematic review and meta-analysis of the odds ratios for opium use and the risk of bladder cancer. PLoS ONE, 2017, 12, e0178527.	1.1	38
584	Desethylamiodaroneâ€”A metabolite of amiodaroneâ€”Induces apoptosis on T24 human bladder cancer cells via multiple pathways. PLoS ONE, 2017, 12, e0189470.	1.1	17
585	Contemporary Management and Trends in the Treatment of Upper Tract Urothelial Carcinoma. World Journal of Nephrology and Urology, 2015, 4, 189-200.	0.3	1
586	Cigarette smoke induced urocytic epithelial mesenchymal transition via MAPK pathways. Oncotarget, 2017, 8, 8791-8800.	0.8	26
587	Functional and therapeutic significance of EZH2 in urological cancers. Oncotarget, 2017, 8, 38044-38055.	0.8	21
588	Sulfatase-1 overexpression indicates poor prognosis in urothelial carcinoma of the urinary bladder and upper tract. Oncotarget, 2017, 8, 47216-47229.	0.8	26
589	Epigenetic inactivation of <i>VGF</i> associated with Urothelial Cell Carcinoma and its potential as a non-invasive biomarker using urine. Oncotarget, 2014, 5, 3350-3361.	0.8	17
590	Novel robust biomarkers for human bladder cancer based on activation of intracellular signaling pathways. Oncotarget, 2014, 5, 9022-9032.	0.8	43
591	Targeting Hsp90 in urothelial carcinoma. Oncotarget, 2015, 6, 8454-8473.	0.8	31
592	Methylomics analysis identifies ZNF671 as an epigenetically repressed novel tumor suppressor and a potential non-invasive biomarker for the detection of urothelial carcinoma. Oncotarget, 2015, 6, 29555-29572.	0.8	32

#	ARTICLE	IF	CITATIONS
593	Residual tumor micro-foci and overwhelming regulatory T lymphocyte infiltration are the causes of bladder cancer recurrence. <i>Oncotarget</i> , 2016, 7, 6424-6435.	0.8	22
594	Low expression of protocadherin7 (PCDH7) is a potential prognostic biomarker for primary non-muscle invasive bladder cancer. <i>Oncotarget</i> , 2016, 7, 28384-28392.	0.8	18
595	Differential association for <i>N</i> -acetyltransferase 2 genotype and phenotype with bladder cancer risk in Chinese population. <i>Oncotarget</i> , 2016, 7, 40012-40024.	0.8	7
596	Immunobiology and immunotherapy in genitourinary malignancies. <i>Annals of Translational Medicine</i> , 2016, 4, 270-270.	0.7	14
597	Eriocalyxin B inhibits proliferation and induces apoptosis through downregulation of Bcl-2 and activation of caspase-3 in human bladder cancer cells. <i>Bangladesh Journal of Pharmacology</i> , 2013, 8, .	0.1	2
599	MicroRNA-34a inhibits bladder cancer cell migration and invasion, and upregulates PTEN expression. <i>Oncology Letters</i> , 2019, 18, 5549-5554.	0.8	13
600	Low PTEN expression and overexpression of phosphorylated Akt ^{Ser473} and Akt ^{Thr308} are associated with poor overall survival in upper tract urothelial carcinoma. <i>Oncology Letters</i> , 2020, 20, 1-1.	0.8	2
601	Epidermal growth factor receptor expression in urinary bladder cancer. <i>Indian Journal of Urology</i> , 2011, 27, 208.	0.2	34
602	Human epidermal growth factor receptor 2/neu overexpression in urothelial carcinoma of the bladder and its prognostic significance: Is it worth hype?. <i>South Asian Journal of Cancer</i> , 2015, 04, 115-117.	0.2	14
603	Occupation, smoking, opium, and bladder cancer: A case-control study. <i>South Asian Journal of Cancer</i> , 2015, 04, 111-114.	0.2	13
604	A review of bladder cancer in Sub-Saharan Africa: A different disease, with a distinct presentation, assessment, and treatment. <i>Annals of African Medicine</i> , 2018, 17, 99.	0.2	14
605	Systemic therapy in bladder cancer. <i>Indian Journal of Urology</i> , 2017, 33, 118.	0.2	9
606	New therapies in nonmuscle invasive bladder cancer treatment. <i>Indian Journal of Urology</i> , 2018, 34, 11.	0.2	35
607	Unusual Patterns of Thoracic Metastasis of Urinary Bladder Carcinoma. <i>Journal of Clinical Imaging Science</i> , 2017, 7, 23.	0.4	6
608	Assessment of microsatellite instability for screening bladder cancer in high-risk population. <i>Journal of Cancer Research and Therapeutics</i> , 2018, 14, 916-920.	0.3	3
609	Parafibromin Staining Characteristics in Urothelial Carcinomas and Relationship with Prognostic Parameters. <i>Journal of Pathology and Translational Medicine</i> , 2015, 49, 389-395.	0.4	7
610	Detecting Metastatic Bladder Cancer Using ¹⁸ F-Fluorodeoxyglucose Positron-Emission Tomography/Computed Tomography. <i>Cancer Research and Treatment</i> , 2015, 47, 834-843.	1.3	17
611	Identification of Significant Prognostic Tissue Markers Associated with Survival in Upper Urinary Tract Urothelial Carcinoma Patients Treated with Radical Nephroureterectomy: A Retrospective Immunohistochemical Analysis Using Tissue Microarray. <i>Cancer Research and Treatment</i> , 2020, 52, 128-138.	1.3	5

#	ARTICLE	IF	CITATIONS
612	The Etiology of Bladder Cancer and its Prevention. Journal of Cancer Science & Therapy, 2013, 05, .	1.7	15
613	Effect of siRNA targeting EZH2 on cell viability and apoptosis of bladder cancer T24 cells. Genetics and Molecular Research, 2014, 13, 9939-9950.	0.3	9
614	Effectiveness of spinal anesthesia combined with obturator nerve blockade in preventing adductor muscle contraction during transurethral resection of bladder tumor. Turkish Journal of Urology, 2017, 43, 507-511.	1.3	4
615	Wpływ czynników środowiskowych na rozwój raka pęcherza moczowego. Nowotwory, 2015, 65, 35-41.	0.1	2
616	The NQO1 rs1800566 Polymorphism and Risk of Bladder Cancer: Evidence from 6,169 Subjects. Asian Pacific Journal of Cancer Prevention, 2012, 13, 6343-6348.	0.5	11
617	GSTP1 Gene Ile105Val Polymorphism Causes an Elevated Risk for Bladder Carcinogenesis in Smokers. Asian Pacific Journal of Cancer Prevention, 2013, 14, 6375-6378.	0.5	10
618	Cancer Incidence in Southwest of Iran: First Report from Khuzestan Population-Based Cancer Registry, 2002-2009. Asian Pacific Journal of Cancer Prevention, 2013, 14, 7517-7522.	0.5	50
619	Urinary Bladder Cancer Risk Factors: A Lebanese Case-Control Study. Asian Pacific Journal of Cancer Prevention, 2013, 14, 3205-3211.	0.5	32
620	Oxidative Stress Induces Hypomethylation of LINE-1 and Hypermethylation of the RUNX3 Promoter in a Bladder Cancer Cell Line. Asian Pacific Journal of Cancer Prevention, 2013, 14, 3773-3778.	0.5	46
621	OK-432 Suppresses Proliferation and Metastasis by Tumor Associated Macrophages in Bladder Cancer. Asian Pacific Journal of Cancer Prevention, 2015, 16, 4537-4542.	0.5	13
622	Incidence and Mortality of Bladder Cancer and their Relationship with Development in Asia. Asian Pacific Journal of Cancer Prevention, 2015, 16, 7365-7374.	0.5	48
623	Pemetrexed in Treating Patients with Metastatic Bladder Cancer. Asian Pacific Journal of Cancer Prevention, 2015, 16, 3839-3841.	0.5	1
624	Epidemiology, Incidence and Mortality of Bladder Cancer and their Relationship with the Development Index in the World. Asian Pacific Journal of Cancer Prevention, 2016, 17, 381-386.	0.5	100
625	Diabetes Mellitus and Obesity as Risk Factors for Bladder Cancer Prognosis: A Systematic Review and Meta-Analysis. Frontiers in Endocrinology, 2021, 12, 699732.	1.5	16
626	FGFR3 Germline Mutations Identified in Skeletal Dysplasia Significantly Cause Low-Grade and Low-Stage Bladder Cancer by Somatic Mutations. UroToday International Journal, 2010, 03, .	0.1	0
627	Bladder cancer - When will the paradigm change?. Indian Journal of Urology, 2011, 27, 161.	0.2	0
629	Bladder Cancer Biology. , 0, , .		1
630	A study of p53 expression in transitional cell carcinoma of urinary bladder in Erbil. Zanco Journal of Medical Sciences, 2012, 16, 248-255.	0.0	0

#	ARTICLE	IF	CITATIONS
631	Association of Chemokine and Chemokine Receptor Gene Polymorphis (MCP1 A-2518G and CCR2-V64I) with Urinary Bladder Cancer: A Study in Kashmiri Population. American Journal of Molecular and Cellular Biology, 0, , .	0.0	1
632	Anesthesia for Urological Endoscopic Procedures. , 2014, , 35-51.		0
634	Radical Cystectomy in Elderly Patients, Single Center, 25 Years Experience. Clinical Medicine Research, 2014, 3, 206.	0.0	0
635	Nierenbecken- und Harnleiterkarzinom. , 2014, , 399-413.		0
636	Smoking and urinary bladder cancer: A case-control study in Basrah. The Medical Journal of Basrah University, 2014, 32, 1-7.	0.1	0
637	The Association Between the Clinicopathological Characteristics and the Recurrence and Progression in Patients with Non-Muscle Invasive Bladder Cancer. Abant Medical Journal, 2015, 4, 243-250.	0.0	0
640	Urothelkarzinom der Harnblase: Epidemiologie, Ä„tiologie und Risikofaktoren. , 2015, , 1-11.		0
641	The Importance of Lymphovascular Invasion at Radical Cystectomy. Clinical Medicine Research, 2015, 4, 34.	0.0	0
642	Postoperative Radiotherapy in Bladder Cancer Patients: 5-Year Institutional Experience of National Cancer Institute, Cairo University. Journal of Cancer Therapy, 2015, 06, 579-593.	0.1	0
644	Holmium: yttrium-aluminum-garnet (Ho:YAG) laser for resection of bladder tumor in a pediatric patient. Pediatric Urology Case Reports, 2015, 2, 10-10.	0.1	0
645	Urothelkarzinom der Harnblase: Epidemiologie, Ä„tiologie und Risikofaktoren. , 2016, , 695-702.		0
646	Evaluating the Prevalence of the Epidermal Growth Factor Receptor in Transitional Cell Carcinoma of Bladder and its Relationship With Other Prognostic Factors. Iranian Journal of Cancer Prevention, 2016, InPress, e4022.	0.7	5
647	Circulating Levels of M30 and M65 Molecules in Transitional Cell Carcinoma of the Bladder and Their Relation to Tumor Progression. Iranian Journal of Cancer Prevention, 2016, In Press, e4086.	0.7	4
648	The Use of Regional Anesthesia in Radical Cystectomy in Muscle-Invasive Bladder Cancer Patients. Emergency Medicine, 2016, .	0.0	0
649	A Preliminary Study for the Development of Clinical Practice Guidelines of Korean Medicine for Bladder Cancer. The Journal of Internal Korean Medicine, 2016, 37, 911-928.	0.0	0
650	The Relation between Survivin Gene Expression and Urinary Bladder Cancer Disease. Hospice and Palliative Medicine International Journal, 2017, 1, .	0.2	1
651	Vinflunine in the Treatment of Upper Tract Urothelial Carcinoma “ Subgroup Analysis of an Observational Study. Anticancer Research, 2017, 37, 6437-6442.	0.5	1
652	Psychometric Evaluation of a Patient-Reported Symptom Index for Nonmuscle Invasive Bladder Cancer: Field Testing Protocol. JMIR Research Protocols, 2017, 6, e216.	0.5	2

#	ARTICLE	IF	CITATIONS
653	Narrow Band Imaging in the Evaluation of Upper Tract Urothelial Cancer. , 2018, , 129-143.		0
654	UPPER TRACT UROTHELIAL CARCINOMA: MORPHOLOGY, DIAGNOSTICS AND TREATMENT. Medical Visualization, 2018, , 78-92.	0.1	0
655	Study of Clinicopathological Spectrum and Pattern of Expression of Cyclooxygenaseâ€™2 in Urothelial Carcinomas of Bladder. Indian Journal of Medical and Paediatric Oncology, 2018, 39, 172-177.	0.1	0
656	Expression profiles of proto-oncogene TWIST1 and tumor metastasis suppressor gene LASS2 in bladder cancer. Cellular and Molecular Biology, 2018, 64, 66.	0.3	1
657	Quantitative and qualitative characteristics of polypeptide pool in patients with bladder cancer. ScienceRise Biological Science, 2018, .	0.1	0
658	Metastatic Pleural Effusion: An Unusual Presentation of Urothelial Bladder Carcinoma. Cureus, 2019, 11, e4619.	0.2	3
659	LINC00978 promotes bladder cancer cell proliferation, migration and invasion by sponging miRâ€™4288. Molecular Medicine Reports, 2019, 20, 1866-1872.	1.1	7
660	Changes in the expression of markers in the glioma tissue of rats with ascariasis. Vestnik of Vitebsk State Medical University, 2019, 18, 74-80.	0.1	0
661	Lessons from Hands-Free Data Entry in Flexible Cystoscopy with Glass for Future Smart Assistance. Computer Communications and Networks, 2020, , 63-87.	0.8	0
662	Ureteroscopic Management of Upper Tract Urothelial Carcinoma. , 2020, , 205-220.		0
663	Aggressive treatment for urothelial cancer-complete urinary tract extirpation: Operative feasibility in two cases. Turkish Journal of Urology, 2019, 45, 393-397.	1.3	4
664	Small cell carcinoma of the bladder presenting with paraneoplastic syndrome of inappropriate antidiuretic hormone. BMJ Case Reports, 2019, 12, e232128.	0.2	1
665	The importance of clinical and pathological features in bladder cancer and its effects on disease course. Dicle Medical Journal, 0, , 821-829.	0.2	0
666	Hemoglobin Level as a Prognostic Factor for Locally Advanced Bladder Cancer Patients Treated with Radical Radiotherapy. Journal of Cancer and Tumor International, 0, , 48-56.	0.1	0
667	Proteolytic parameter changes in the plasma of patients with bladder cancer â€™ depending on tumor stage. Current Issues in Pharmacy and Medical Sciences, 2020, 33, 67-71.	0.1	1
669	Bladder Cancer: Overview, Epidemiology, Initial Presentation and Diagnosis. , 2021, , 141-157.		1
670	High S100A7 expression is associated with early muscle invasion and poor survival in bladder carcinoma. Annals of Diagnostic Pathology, 2021, 56, 151847.	0.6	0
671	Benzidine promotes the stemness of bladder cancer stem cells via activation of the Sonic hedgehog pathway. Oncology Letters, 2020, 21, 146.	0.8	5

#	ARTICLE	IF	CITATIONS
672	COMPARISON OF BLADDER CANCER CELLS APOPTOSIS INDUCED BY METFORMIN, CISPLATIN, AND COMBINATION OF METFORMIN-CISPLATIN: IN VITRO STUDY. <i>Jurnal Urologi Indonesia</i> , 2020, 27, 103-110.	0.0	0
673	Correlation of Muscle Invasion in Bladder Cancer with Cell Adhesion Properties and Oncoprotein Overexpression Using E-Cadherin and HER2/neu Immunohistochemical Markers.. <i>Open Access Macedonian Journal of Medical Sciences</i> , 2020, 8, 43-48.	0.1	0
674	Vascular Endothelial Growth Factor Polymorphism in Bladder Cancer: A Review. <i>Open Access Macedonian Journal of Medical Sciences</i> , 2020, 8, 31-36.	0.1	1
675	Consumption of Fruits, Vegetables and Bladder Cancer Risk: A Systematic Review and Meta-Analysis of Prospective Cohort Studies. <i>Nutrition and Cancer</i> , 2022, 74, 2003-2016.	0.9	4
676	Nierenbecken- und Harnleiterkarzinom. , 2014, , 399-413.		0
677	Prognostic Implications of Deep Muscle Invasion and High Grade for Bladder Urothelial Carcinoma. <i>Cureus</i> , 2020, 12, e10802.	0.2	0
678	CYP2E1 and NQO1 genotypes and bladder cancer risk in a Lebanese population. <i>International Journal of Molecular Epidemiology and Genetics</i> , 2013, 4, 207-17.	0.4	11
679	Metabolomics in bladder cancer: a systematic review. <i>International Journal of Clinical and Experimental Medicine</i> , 2015, 8, 11052-63.	1.3	36
680	MiRNA-29c regulates cell growth and invasion by targeting CDK6 in bladder cancer. <i>American Journal of Translational Research (discontinued)</i> , 2015, 7, 1382-9.	0.0	37
681	Standard cystectomy fits all: truth or myth?. <i>Translational Andrology and Urology</i> , 2015, 4, 254-60.	0.6	10
682	Extracellular MicroRNA in liquid biopsy: applicability in cancer diagnosis and prevention. <i>American Journal of Cancer Research</i> , 2016, 6, 1461-93.	1.4	40
683	Analysis of bladder cancer tumor CpG methylation and gene expression within The Cancer Genome Atlas identifies as a prognostic biomarker for basal-like bladder cancer. <i>American Journal of Cancer Research</i> , 2017, 7, 1850-1862.	1.4	5
684	Epidemiology and Hospitalization Cost of Bladder Cancer in Kerman Province, Southeastern Iran. <i>Iranian Journal of Public Health</i> , 2018, 47, 567-574.	0.3	1
685	Urinary Bladder Tumors Clinical and Statistical Retrospective Study. <i>Current Health Sciences Journal</i> , 2018, 44, 64-70.	0.2	1
687	Gene Polymorphisms Are Associated with Urinary Bladder Cancer in an Iranian Population. <i>Reports of Biochemistry and Molecular Biology</i> , 2019, 8, 194-199.	0.5	3
688	MicroRNA-195 inhibits epithelial-mesenchymal transition via downregulating CDK4 in bladder cancer. <i>International Journal of Clinical and Experimental Pathology</i> , 2018, 11, 3891-3902.	0.5	2
689	Loss of E-cadherin expression in recurrent non-invasive urothelial carcinoma of the bladder. <i>International Journal of Clinical and Experimental Pathology</i> , 2018, 11, 4163-4168.	0.5	5
690	The antitumor effect of the novel cancer-specific adenovirus Ad-VEGFR on bladder cancer in vitro and in vivo. <i>International Journal of Clinical and Experimental Pathology</i> , 2018, 11, 4795-4805.	0.5	0

#	ARTICLE	IF	CITATIONS
691	Protein kinase TTK promotes proliferation and migration and mediates epithelial-mesenchymal transition in human bladder cancer cells. <i>International Journal of Clinical and Experimental Pathology</i> , 2018, 11, 4854-4861.	0.5	4
692	Expression of circular RNA circASXL1 correlates with TNM classification and predicts overall survival in bladder cancer. <i>International Journal of Clinical and Experimental Pathology</i> , 2017, 10, 8495-8502.	0.5	12
693	Methylation of the suppressor of cytokine signaling 3 gene (SOCS3) in bladder cancer. <i>International Journal of Clinical and Experimental Pathology</i> , 2017, 10, 11326-11334.	0.5	0
694	Cigarette smoke supports stemness and epithelial-mesenchymal transition in bladder cancer stem cells through SHH signaling. <i>International Journal of Clinical and Experimental Pathology</i> , 2020, 13, 1333-1348.	0.5	1
695	Molecular Pathways in Low and High-grade Non-muscle Invasive Bladder Cancer as Revealed by Several OMICs Data Analyses. , 2021, 1, .		0
696	Effect of Traditional Chinese Medicine Combined with Bladder Perfusion with Hydroxycamptothecin on Color Ultrasound and Clinical Efficacy in Patients with Bladder Cancer Surgery. <i>Evidence-based Complementary and Alternative Medicine</i> , 2021, 2021, 1-8.	0.5	3
697	LncRNA TUG1 promotes bladder cancer malignant behaviors by regulating the miR-320a/FOXQ1 axis. <i>Cellular Signalling</i> , 2022, 91, 110216.	1.7	13
698	Performing laparoscopic radical cystectomy is feasible for the elderly with marginal cardiopulmonary function. <i>Urological Science</i> , 2018, 29, 20.	0.2	1
699	Family History and Risk of Bladder Cancer: An Analysis Accounting for First- and Second-degree Relatives. <i>Cancer Prevention Research</i> , 2022, 15, 319-326.	0.7	5
700	Trial-based Cost-effectiveness Analysis of an Immediate Postoperative Mitomycin C Instillation in Patients with Non-muscle-invasive Bladder Cancer. <i>European Urology Open Science</i> , 2022, 37, 7-13.	0.2	1
701	Efficacy of Surgery on the Primary Tumour in Patients with Metastatic Bladder Cancer: A Comprehensive Review. <i>Bladder Cancer</i> , 2022, , 1-17.	0.2	0
702	Socio-economic burden of disease: Survivorship costs for bladder cancer. <i>Journal of Cancer Policy</i> , 2022, 32, 100326.	0.6	13
703	Diagnostic performance of the Bladder EpiCheck methylation test and photodynamic diagnosis-guided cystoscopy in the surveillance of high-risk non-muscle invasive bladder cancer: A single centre, prospective, blinded clinical trial. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 105.e11-105.e18.	0.8	13
704	Marital status independently predicts survival of patients with upper urinary tract urothelial carcinoma: A population-based study. <i>Journal of Cancer Research and Therapeutics</i> , 2021, 17, 1709.	0.3	5
705	Identifying the grade of bladder cancer cells using microfluidic chips based on impedance. <i>Analyst</i> , 2022, 147, 1722-1729.	1.7	3
706	FimH confers mannose-targeting ability to Bacillus Calmette-Guerin for improved immunotherapy in bladder cancer. , 2022, 10, e003939.		8
707	PARP inhibitors chemopotentiate and synergize with cisplatin to inhibit bladder cancer cell survival and tumor growth. <i>BMC Cancer</i> , 2022, 22, 312.	1.1	3
708	Comparative Analysis of Differentially Mutated Genes in Non-Muscle and Muscle-Invasive Bladder Cancer in the Chinese Population by Whole Exome Sequencing. <i>Frontiers in Genetics</i> , 2022, 13, 831146.	1.1	5

#	ARTICLE	IF	CITATIONS
709	Bladder Cancer Extracellular Vesicles Elicit a CD8 T Cell-Mediated Antitumor Immunity. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2904.	1.8	7
710	Evaluation of bladder washings cytology in diagnosis of neoplasms of urinary bladder. <i>IP Archives of Cytology and Histopathology Research</i> , 2022, 7, 20-25.	0.0	0
711	Current standards and practice changing studies in genitourinary (GU) cancers—a review of studies in localized/early GU cancers. <i>ESMO Open</i> , 2022, 7, 100432.	2.0	0
712	Predictive value of inflammatory indices LMR, PLR and NLR in patients with muscle-invasive bladder cancer. <i>Urologicheskie Vedomosti</i> , 2021, 11, 285-294.	0.4	0
713	Utility of Contemporary Health Screening in the Diagnosis of Bladder Cancer. <i>Diagnostics</i> , 2022, 12, 1040.	1.3	0
724	Human papillomavirus (HPV)-induced neoplasia in the urinary bladder: a missing link?. <i>Histology and Histopathology</i> , 2016, 31, 595-600.	0.5	8
726	A clinical case of a big urethral recurrence after cystectomy in a patient with invasive bladder cancer. <i>Almanah Kliničeskoj Mediciny</i> , 2022, 50, 71-75.	0.2	0
729	(Nano)platforms in bladder cancer therapy: Challenges and opportunities. <i>Bioengineering and Translational Medicine</i> , 2023, 8, .	3.9	46
730	miR-1307-5p suppresses proliferation and tumorigenesis of bladder cancer via targeting MDM4 and the Hippo signaling pathway. <i>Discover Oncology</i> , 2022, 13, .	0.8	2
731	Assessment of Tolerability, Response and Complications of Concurrent Chemoradiation With Capecitabine and Cisplatin in Muscle-Invasive Bladder Cancer; A Single Arm Study. <i>Clinical Genitourinary Cancer</i> , 2023, 21, 105.e1-105.e6.	0.9	0
732	A Clinicopathological Correlation of Bladder Cancer in Young and Old Patients: Our Experience and Review of Literature. <i>Indian Journal of Surgical Oncology</i> , 0, , .	0.3	0
733	Diagnostic Potential of Circulating Tumor Cells, Urinary MicroRNA, and Urinary Cell-Free DNA for Bladder Cancer: A Review. <i>International Journal of Molecular Sciences</i> , 2022, 23, 9148.	1.8	11
734	EphrinB2 Inhibition and Pembrolizumab in Metastatic Urothelial Carcinoma. <i>Journal of Clinical Oncology</i> , 2023, 41, 640-650.	0.8	9
735	Curcumin in the treatment of urological cancers: Therapeutic targets, challenges and prospects. <i>Life Sciences</i> , 2022, 309, 120984.	2.0	14
736	Interferon gamma expression and mortality in unselected cohorts of urothelial bladder cancer patients. <i>PLoS ONE</i> , 2022, 17, e0271339.	1.1	3
737	Epidemiology of Bladder Cancer in the Arab World: 2019 Global Burden of Disease Data. <i>Asian Pacific Journal of Cancer Prevention</i> , 2022, 23, 2907-2919.	0.5	2
739	Secular trends of morbidity and mortality of prostate, bladder, and kidney cancers in China, 1990 to 2019 and their predictions to 2030. <i>BMC Cancer</i> , 2022, 22, .	1.1	9
740	Hyperbaric oxygen enhanced the chemotherapy of mitochondrial targeting molecule IR-780 in bladder cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 683-699.	1.2	2

#	ARTICLE	IF	CITATIONS
741	Molecular Detection of Epstein-Barr virus in Biopsy Samples of Patients Suffering from Bladder Cancer in Bushehr Province, Iran. Iranian South Medical Journal, 2022, 25, 326-339.	0.2	0
742	Molecular and epidemiological characterization of bladder tumors. , 2023, , 299-310.		0
743	Impact of intravesical Bacillus Calmette-Guérin and chemotherapy on the bladder microbiome in patients with non-muscle invasive bladder cancer. Frontiers in Cellular and Infection Microbiology, 0, 13, .	1.8	6
744	A New Global Voice for People Affected by Bladder Cancer. European Medical Journal Urology, 0, , 42-43.	0.0	0
745	Urothelial carcinoma of urinary bladder with histologic grading: a study in a tertiary care hospital, Bangladesh. International Journal of Research in Medical Sciences, 2023, 11, 746-750.	0.0	0
746	Collaborative deep learning improves disease-related circRNA prediction based on multi-source functional information. Briefings in Bioinformatics, 2023, 24, .	3.2	9
747	piRNA-Based Cancer Therapy in Hypoxic Tumor. , 2023, , 161-180.		0
769	THE EFFECT OF IMMUNOLOGICAL BIOMARKERS - NLR, PLR, LMR, PD-L1 ON THE SURVIVAL OF PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER. , 0, , .		0